PRMT5 inhibitor as well as pharmaceutical composition, pharmaceutical preparation and application thereof
By developing novel small molecule compounds to inhibit PRMT5, the problem of insufficient biological performance of existing inhibitors has been solved, achieving effective treatment and prevention of PRMT5-mediated diseases, and demonstrating excellent in vitro inhibitory activity and pharmacodynamic properties.
Patent Information
- Application Number
- CN202410564490.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-12
AI Technical Summary
Existing PRMT5 inhibitors have insufficient biological properties and safety issues in clinical applications, making them difficult to effectively prevent and treat PRMT5-mediated diseases.
A novel small molecule compound, having a compound of Formula I or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label, or prodrug thereof, has been developed for highly efficient inhibition of PRMT5 and has been prepared into pharmaceutical compositions and formulations.
This compound exhibits excellent in vitro inhibitory activity and pharmacodynamic properties, and can effectively prevent and treat PRMT5-mediated diseases, such as various cancers and cardiovascular diseases, showing promising application prospects and clinical significance.
Smart Images

Figure CN118930582A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of pharmaceutical chemistry, and specifically relates to a small molecule inhibitor targeting PRMT5, a pharmaceutical composition and a pharmaceutical preparation containing the same, and medical uses thereof. Background Art
[0002] Arginine methylated modification is one of the common types of protein post-translational modification, which refers to the formation of methylation modification on the arginine guanidinium group of the substrate protein. The enzyme that catalyzes the formation of arginine methylation modification is called protein arginine methyltransferase (PRMT). There are 9 members in the arginine methyltransferase family (PRMT1 to PRMT9). They catalyze the methylation of various substrate proteins, affect the stability, localization, activity of substrate proteins, or interact with substrate proteins, and participate in the regulation of various physiological and pathological processes. Studies have found that PRMT plays a regulatory role in the occurrence, development, drug resistance or metastasis of tumors, showing its potential as a tumor biomarker or therapeutic target. Currently, a number of PRMT-specific inhibitors have been developed, and some have entered the clinical trial stage.
[0003] Protein arginase methyltransferase 5 (PRMT5) is an epigenetic target with clinical potential. It is a type II arginine methyltransferase that modifies histones and other proteins post-translationally through symmetric dimethylation. PRMT5 plays an important role in regulating key cellular processes, including DNA repair, cell cycle progression, transcriptional regulation, and RNA splicing. Upregulation of PRMT5 levels can lead to the proliferation and invasion of tumor cells in a variety of different cancers, including glioblastoma, melanoma, blood tumors (such as leukemia, lymphoma, multiple myeloma), bladder urothelial carcinoma, colorectal cancer, lung cancer, gastric cancer, ovarian cancer, prostate cancer, etc. At present, drugs that act as PRMT5 inhibitors are all in the clinical stage, among which AMG-193 from Amgen, MRTX1719 from Mirati Therapeutics, SKL27969 from SK Life Science, and TNG908 from Tango Therapeutics have made the fastest progress and have completed Phase I clinical trials.
[0004] In summary, the development of new PRMT5 inhibitors has very important clinical value and significance. Summary of the invention
[0005] Problem that the invention aims to solve
[0006] The present application is intended to provide a novel small molecule PRMT5 inhibitor, in particular a new compound with good biological properties that can be safely applied to the human body. The present application is also intended to provide a pharmaceutical composition and a pharmaceutical preparation containing the inhibitor, and its use in preventing and / or treating PRMT5-related diseases.
[0007] Solutions for solving problems
[0008] In a first aspect, the present application provides a compound having a structure of Formula I or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance (e.g., deuterated substance) or prodrug thereof:
[0009]
[0010] in:
[0011] represents a single bond or a double bond;
[0012] Every R 1 Each independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is optionally substituted with one or more halogen, cyano, hydroxyl, amino, nitro, C 1-6 Haloalkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl substituted;
[0013] Every R 2 Each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is optionally substituted with one or more halogen, cyano, hydroxyl, amino, nitro, C 1-6 Haloalkyl, C 1-6 Alkyl, C3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl substituted;
[0014] Every R 3 are each independently selected from H, halogen, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 3-10 Cycloalkyl and 3-10 membered heterocyclic group;
[0015] Or, R 1 and R 3 Connected to each other to form a 5-10 membered heterocyclic group;
[0016] A is selected from 3-10 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl;
[0017] R 4 Selected from H, halogen, cyano, hydroxyl, nitro, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR 1 R 2 、-C(=O)R 1 、-NHC(=O)R 1 、-SO2R 1 、-SOR 1 , C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, oxazabicyclo[3.2.1]octanyl, -C(=S)SR 6 and-P(=O)R 11 R 12 ; said C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR 1 R 2 、-C(=O)R 1 、-NHC(=O)R 1 、-SO2R 1 、-SOR 1 , C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, oxazabicyclo[3.2.1]octanyl, -C(=S)SR 6 or -P(=O)R 11 R12 Optionally substituted with one or more substituents selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, halogen, hydroxyl, amino, cyano, nitro, =NH, =NR 3 、-C(=S)SR 6 、-(C 1-6 Alkylene)-OH, -(C 1-6 Alkylene)-NH2, C 1-6 Haloalkyl and -P(=O)R 11 R 12 ;
[0018] R 5 Selected from H, -P(=O)R 11 R 12 , -R a -P(=O)R 11 R 12 , -R a -C(=S)SR 6 and-C(=S)SR 6 ;and,
[0019] R 4 and R 5 Not at the same time hydrogen;
[0020] Every R 11 and R 12 Each independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, NH(R c )-(C 1-6 Alkylene)- and N(R c )(C 1-6 Alkyl)-(C 1-6 Alkylene)-, or, R 11 and R 12 are connected to each other to form a 5-10 membered heterocyclic group; 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, 5-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl is optionally substituted with one or more R c replace;
[0021] Every R c are each independently selected from H, halogen, O=, HN=, C 1-6 Alkoxy, (C 1-6Alkyl)-N=, C 1-6 Alkyl, (C 1-6 alkyl)-C(=O)-, (C 1-6 Alkyl)-SO2-, (C 3-6 Cycloalkyl)-SO2-, (C 1-6 alkyl)-OC(=O)-, (C 1-6 alkyl)-O-(C 1-6 Alkylene)-, (C 1-6 alkyl)-O-(C 1-6 Alkylene)-C(=O)-, NH2-C(=O)-, (C 1-6 alkyl)-NH-C(=O)-, (C 1-6 Alkyl)2N-C(=O)-, NH2-(C 1-6 Alkylene)-C(=O)-, (C 1-6 alkyl)-NH-(C 1-6 Alkylene)-C(=O)-, (C 1-6 Alkyl)2N-(C 1-6 Alkylene)-C(=O)-, NH2-C(=O)-(C 1-6 Alkylene)-, (C 1-6 alkyl)-NH-C(=O)-(C 1-6 Alkylene)-, (C 1-6 alkyl)2N-C(=O)-(C 1-6 Alkylene)-, C 3-6 Cycloalkyl, (C 3-6 Cycloalkyl)-C(=O)-, (C 3-6 Cycloalkyl)-(C 1-6 alkylene)-, 3-10 membered heterocyclic group, (3-10 membered heterocyclic group)-C(=O)-, (3-10 membered heterocyclic group)-(C 1-6 Alkylene)-, (C 6-10 Aryl)-(C 1-6 Alkylene)- and C substituted by one or more hydroxyl or cyano groups 1-6 Alkyl; when R c When it is not H, halogen or O=, R c optionally substituted with one or more halogens;
[0022] R a Selected from C 1-6 Alkylene, -(C 3-8 cycloalkyl)-(C=O)-, 3-10 membered heterocyclyl, 5-10 membered heteroaryl and C 6-10 Aryl; the 3-10 membered heterocyclic group, 5-10 membered heteroaryl or C 6-10 The aryl group is optionally substituted with one or more halogen, cyano, hydroxy, nitro, amino, aldehyde, C1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Haloalkoxy substitution;
[0023] Every R 6 Each independently selected from H, C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-(3-8 membered heterocyclic group), C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -(C 1-6 Alkylene)-OH, -(C 1-6 Alkylene)-NH2, -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-NH-(C 1-6 Alkyl), -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)NH(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)N(C 1-6 Alkyl)2, -SOR 1 and-SO2R 1 ;
[0024] X1 for CR 3 or N;
[0025] X2 for CR 3 or N;
[0026] X3 for CR 3 , C(R 3 )2. NR 3 , C=O or N;
[0027] X4 for CR 10 or N;
[0028] X5 for CR 9 or N;
[0029] R 7 is H or methyl;
[0030] R 8 Selected from H, halogen, alkynyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy and -(C 1-6 Alkylene)-NH2;
[0031] If present, R 9 is selected from H, halogen, alkynyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy and C 3-10 Cycloalkyl;
[0032] Or, if present, R 8 and R 9 Connect to each other to form C 3-10 Cycloalkenyl, 5-10 membered heterocyclyl or 5-10 membered heteroaryl; the 5-10 membered heterocyclyl or 5-10 membered heteroaryl each independently contains at least one N, O or S;
[0033] If present, R 10 is selected from H, amino, hydroxyl and carboxyl;
[0034] m is 0, 1, 2, 3 or 4;
[0035] Furthermore, the compound having the structure of Formula I satisfies the following conditions at the same time:
[0036] Condition 1: When R 5 is H, and R 1 and R 3 When they are not connected to each other to form a 5-10 membered heterocyclic group, X3 is not N;
[0037] Condition 2: When R 8 and R 9 When connected to form a 5-10 membered heterocyclic group, R 4 For H.
[0038] In a second aspect, the present application provides the following compounds or pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, tautomers, cis-trans isomers, isotope-labeled substances or prodrugs thereof:
[0039]
[0040]
[0041]
[0042]
[0043] In a third aspect, the present application provides a pharmaceutical composition comprising the above-mentioned compound or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, and at least one pharmaceutically acceptable carrier.
[0044] Preferably, in the above-mentioned pharmaceutical composition, the pharmaceutically acceptable carrier includes but is not limited to diluents (or fillers), binders, disintegrants, lubricants, wetting agents, thickeners, glidants, flavoring agents, olfactory agents, preservatives, antioxidants, pH adjusters, solvents, cosolvents, surfactants, opacifiers (opacifiers), etc.
[0045] In a fourth aspect, the present application provides a pharmaceutical preparation, which is made of the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug, or is made of the above-mentioned pharmaceutical composition. Alternatively, the present application provides a pharmaceutical preparation, which contains the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug as an active ingredient.
[0046] In the fifth aspect, the present application provides the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug, or the above-mentioned pharmaceutical composition, or the above-mentioned pharmaceutical preparation for the preparation of a drug for preventing and / or treating a disease mediated at least in part by PRMT5. Alternatively, the present application provides the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug, or the above-mentioned pharmaceutical composition, or the above-mentioned pharmaceutical preparation for preventing and / or treating a disease mediated at least in part by PRMT5. Alternatively, the present application provides a method for preventing and / or treating a disease mediated at least in part by PRMT5, comprising administering the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug, or the above-mentioned pharmaceutical composition, or the above-mentioned pharmaceutical preparation to a subject in need.
[0047] Preferably, the disease at least partially mediated by PRMT5 is cancer, cardiovascular disease or myelofibrosis. More preferably, the cancer includes glioblastoma, melanoma, blood tumors (such as leukemia, lymphoma, multiple myeloma), bladder urothelial carcinoma, colorectal cancer, lung cancer, gastric cancer, ovarian cancer, breast cancer, cervical cancer, squamous cell carcinoma, brain tumor, prostate cancer and myelodysplastic syndrome. More preferably, the cardiovascular disease includes myocardial hypertrophy, heart failure and arrhythmia.
[0048] In a sixth aspect, the present application provides a drug combination comprising the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug, or the above-mentioned pharmaceutical composition, or the above-mentioned pharmaceutical preparation, and at least one additional therapeutic agent.
[0049] Effects of the Invention
[0050] The compounds of the present application have excellent in vitro inhibitory activity against PRMT5, can be used as PRMT5 small molecule inhibitors, and have excellent pharmacodynamic properties and metabolic stability. The compounds of the present application can be used to prevent / treat diseases that are at least partially mediated by PRMT5, and to prepare drugs for preventing / treating such diseases, and have good application prospects and important clinical significance. DETAILED DESCRIPTION
[0051] Before further describing the present application, it should be understood that the present application is not limited to the specific embodiments described herein; it should also be understood that the terms used herein are only used to describe and not to limit specific embodiments. In the absence of a definition, the term should be interpreted according to the meaning commonly understood by those skilled in the art.
[0052] [Definition of terms]
[0053] Unless otherwise stated, the following terms have the following meanings.
[0054] The term "pharmaceutically acceptable salt" refers to a salt of the compound of the present application that is substantially non-toxic to an organism. Pharmaceutically acceptable salts generally include, but are not limited to, salts formed by reacting the compound of the present application with a pharmaceutically acceptable inorganic acid or organic acid, which are also known as acid addition salts. Common inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid (which can form sulfates or acid sulfates), phosphoric acid (which can form phosphates or acid phosphates), etc. Common organic acids include, but are not limited to, trifluoroacetic acid, citric acid (which can form citric acid monosalt, disalt or trisalt), maleic acid (which can form maleic acid monosalt or disalt), fumaric acid (which can form fumaric acid monosalt or disalt), succinic acid (which can form succinic acid monosalt or disalt), tartaric acid (which can form tartaric acid monosalt or disalt), oxalic acid (which can form oxalic acid monosalt or disalt), malonic acid (which can form malonic acid monosalt or disalt), malic acid (which can form malic acid monosalt or disalt), oxalic acid (which can form oxalic acid monosalt or disalt), lactic acid, pyruvic acid, salicylic acid, formic acid, acetic acid, propionic acid, benzoic acid, glycolic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. Pharmaceutically acceptable salts may also include salts formed by the compounds of the present application and pharmaceutically acceptable organic or inorganic bases, which are also called base addition salts. Common base addition salts include, but are not limited to, alkali metal salts, such as lithium, sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; organic base salts, such as ammonium salts or N-containing organic bases formed by reacting with N-containing groups. + (C 1-6 Common inorganic or organic bases include, but are not limited to, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, calcium carbonate, ammonia water, triethylamine or tetrabutylammonium hydroxide. Pharmaceutically acceptable salts can be synthesized by general chemical methods.
[0055] The term "hydrate" refers to a substance formed by the combination of a compound of the present invention or a pharmaceutically acceptable salt thereof and water through non-covalent intermolecular forces. Common hydrates include but are not limited to hemihydrates, monohydrates, dihydrates, trihydrates, and the like.
[0056] The term "solvate" refers to a substance formed by the combination of a compound of the present invention or a pharmaceutically acceptable salt thereof and at least one solvent molecule through non-covalent intermolecular forces. The term "solvate" includes "hydrates". Common solvates include, but are not limited to, hydrates, ethanolates, acetonates, etc. It should be understood that the present invention encompasses all solvate forms having PRMT5 inhibitory activity.
[0057] The term "isomers" refers to compounds that have the same number and types of atoms and therefore the same molecular weight, but differ in the arrangement or configuration of the atoms in space.
[0058] The term "stereoisomer" (or "optical isomer") refers to a stable isomer that has a vertical asymmetric plane due to at least one chiral factor (including chiral center, chiral axis, chiral plane, etc.), thereby being able to rotate plane polarized light. Since there are asymmetric centers and other chemical structures that may cause stereoisomerism in the compounds of the present invention, the present invention also includes these stereoisomers and mixtures thereof. Since the compounds of the present invention and their salts include asymmetric carbon atoms, they can exist in the form of a single stereoisomer, a racemate, an enantiomer, and a mixture of diastereomers. Generally, these compounds can be prepared in the form of a racemic mixture. However, if desired, such compounds can be prepared or separated to obtain pure stereoisomers, i.e., single enantiomers or diastereomers, or single stereoisomer-enriched (purity ≥98%, ≥95%, ≥93%, ≥90%, ≥88%, ≥85% or ≥80%) mixtures. As described below, a single stereoisomer of a compound is prepared synthetically from an optically active starting material containing the desired chiral center, or by preparing a mixture of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereoisomers followed by separation or recrystallization, chromatography, use of a chiral resolution agent, or direct separation of the enantiomers on a chiral chromatographic column. Starting compounds with a specific stereochemistry are either commercially available or prepared as described below and resolved by methods well known in the art. The term "enantiomer" refers to a pair of stereoisomers that are non-superimposable mirror images of each other. The term "diastereomer" or "diastereomers" refers to optical isomers that are not mirror images of each other. The term "racemic mixture" or "racemate" refers to a mixture containing equal parts of a single enantiomer (i.e., an equimolar mixture of two R and S enantiomers). The term "non-racemic mixture" refers to a mixture containing unequal parts of a single enantiomer. Unless otherwise stated, all stereoisomeric forms of the compounds of the present invention are within the scope of the present invention.
[0059] The term "tautomer" (or "tautomeric form") refers to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be achieved. For example, proton tautomers (or prototransfer tautomers) include but are not limited to interconversions through proton migration, such as keto-enol isomerization, imine-enamine isomerization, amide-imine alcohol isomerization, etc. Unless otherwise indicated, all tautomeric forms of the compounds of the present application are within the scope of the present application.
[0060] The term "cis-trans isomer" refers to stereoisomers formed by the different positions of atoms (or groups) located on both sides of a double bond or a ring system relative to a reference plane; in cis isomers, the atoms (or groups) are located on the same side of the double bond or the ring system, and in trans isomers, the atoms (or groups) are located on opposite sides of the double bond or the ring system. Unless otherwise indicated, all cis-trans isomeric forms of the compounds of the present application are within the scope of the present application.
[0061] The term "isotope-labeled compound" refers to a compound formed by replacing a specific atom in a structure with an isotope atom thereof. Unless otherwise indicated, the compounds of the present application include various isotopes of H, C, N, O, F, P, S, and Cl, such as 2 H(D), 3 H(T), 13 C. 14 C. 15 N. 17 O. 18 O. 18 F. 31 P. 32 P. 35 S. 36 S and 37 For example, deuterated species may be defined as a compound in which a hydrogen atom is replaced with deuterium (ie, D), and the amount of deuterium at that position greatly exceeds (eg, at least 1000 times exceeds) the abundance of deuterium that occurs naturally.
[0062] The term "prodrug" refers to a derivative compound that can directly or indirectly provide the compound of the present application after being administered to a patient. Particularly preferred derivative compounds or prodrugs are compounds that can improve the bioavailability of the compound of the present application when administered to a patient (e.g., more easily absorbed into the blood), or compounds that promote the delivery of the parent compound to the site of action (e.g., the lymphatic system). Unless otherwise indicated, all prodrug forms of the compounds of the present application are within the scope of the present application, and various prodrug forms are well known in the art.
[0063] The term "aryl" refers to a monocyclic or condensed polycyclic monovalent group having aromaticity, wherein the ring atoms are all C atoms, for example, 6 to 20, 6 to 14 or 6 to 10 carbon atoms. Non-limiting examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl and 1,2,3,4-tetrahydronaphthalene. The term "C 6-10 "Aryl" refers to an aromatic group having 6 to 10 carbon atoms, C 6-10 Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, and 1,2,3,4-tetrahydronaphthalene, and the like.
[0064] The term "heteroaryl" refers to a monocyclic or condensed polycyclic monovalent group having aromaticity, wherein at least one (e.g., 1, 2, 3, or 4) ring atom is a heteroatom selected from N, O, S, and P, and the remaining ring atoms are C, for example, a 5- to 12-membered ring, especially a 5- to 10-membered ring. Non-limiting examples of heteroaryl include, but are not limited to The term "5-10 membered heteroaryl" refers to a heteroaryl group having 5 to 10 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O, S and P. Non-limiting examples of 5-10 membered heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, thiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl and quinolinyl, etc.
[0065] The term "alkyl" refers to a linear or branched monovalent hydrocarbon group containing no unsaturation. 1-4 "Alkyl" refers to an alkyl group having 1 to 4 carbon atoms. 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms, C 1-6 Non-limiting examples of alkyl groups include, but are not limited to, methyl (-CH3), ethyl (-CH2CH3), n-propyl (-CH2CH2CH3), isopropyl (-CH(CH3)2), n-butyl (-CH2CH2CH2CH3), sec-butyl (-CH(CH3)CH2CH3), isobutyl (-CH2CH(CH3)2), tert-butyl (-C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), neopentyl (-CH2C(CH3)3), and the like.
[0066] The term "alkylene" refers to a divalent hydrocarbon group formed by further losing a hydrogen atom from an alkyl group and does not contain unsaturation. 1-4 "Alkylene" refers to an alkylene group having 1 to 4 carbon atoms. 1-6 "Alkylene" refers to an alkylene group having 1 to 6 carbon atoms, C 1-6 Non-limiting examples of alkylene include, but are not limited to, methylene (—CH 2 —), 1,2-ethylene (—CH 2 CH 2 —), 1,1-ethylene (—CH(CH 3 ) —), and the like.
[0067] The term "cycloalkyl" refers to a fully saturated monocyclic or polycyclic (eg, spirocyclic, fused, or bridged) monovalent cyclic hydrocarbon group, for example, having 3 to 10, 3 to 8, or 3 to 6 carbon atoms. 3-10 "Cycloalkyl" refers to a cycloalkyl group having 3 to 10 carbon atoms; the term "C 3-8 "Cycloalkyl" refers to a cycloalkyl group having 3 to 8 carbon atoms; the term "C 3-6"Cycloalkyl" refers to a cycloalkyl group having 3 to 6 carbon atoms. 3-6 Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
[0068] The term "heterocycloalkyl" refers to a fully saturated monocyclic monovalent cyclic hydrocarbon group, at least one (e.g., 1, 2, 3, or 4) of which is a heteroatom selected from N, O, S, and P, and the remaining ring atoms are C, for example, a 3- to 10-membered ring, or a 5- to 10-membered ring, or a 3- to 6-membered ring. The term "3- to 6-membered heterocycloalkyl" refers to a heterocycloalkyl group having 3 to 6 ring atoms, which may contain 1 or 2 heteroatoms selected from N, O, S, and P. Non-limiting examples of "3- to 6-membered heterocycloalkyl" include, but are not limited to, oxirane, thioethane, cyclonitroethane, azetidinyl, oxadiazolyl, thiazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, cyclopentylsulfoxide, cyclopentylsulfone, morpholinyl, piperazinyl, 1,4-thioxanyl, 1,4-dioxanyl, 1,4-diphosphinyl, 1,4-nitrophosphinyl, thiomorpholinyl, 1,3-dithianyl, 1,4-dithianyl, The term "3-10 membered heterocycloalkyl" refers to a heterocycloalkyl group having 3 to 10 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O, S and P. Non-limiting examples of "3-10 membered heterocycloalkyl" include, but are not limited to, the above-listed "3-6 membered heterocycloalkyl", azepanyl, oxepinyl, thiepanyl, etc.
[0069] The term "heterocycloalkenyl" refers to a monocyclic monovalent cyclic hydrocarbon group containing one or two double bonds but no aromaticity, wherein at least one (e.g., 1, 2, 3, or 4) ring atom is a heteroatom selected from N, O, S, and P, and the remaining ring atoms are C, for example, it can be a 3- to 10-membered ring, or a 5- to 10-membered ring, or a 3- to 6-membered ring. The term "3-10-membered heterocycloalkenyl" refers to a heterocycloalkenyl group having 3 to 10 ring atoms, which may contain 1, 2, 3, or 4 heteroatoms selected from N, O, S, and P. Non-limiting examples of "3-10-membered heterocycloalkenyl" include, but are not limited to
[0070] wait.
[0071] The term "heterospirocyclyl" refers to a fully saturated monovalent spirocyclic hydrocarbon radical, at least one (e.g., 1, 2, 3, or 4) of which ring atoms are heteroatoms selected from N, O, S, and P, and the remaining ring atoms are C, for example, 3 to 10 rings, or 5 to 10 rings, or 3 to 6 rings. The term "3-10 membered heterospirocyclyl" refers to a heterospirocyclyl having 3 to 10 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O, S, and P. Non-limiting examples of "3-10 membered heterospirocyclyl" include, but are not limited to, 2,6-diazaspiro[3.3]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, and the like.
[0072] The term "heterobridged ring group" refers to a monovalent group obtained by losing a hydrogen atom from a bridged ring compound in which at least one (e.g., 1, 2, 3 or 4) ring atom is a heteroatom (selected from N, O, S and P). The term "bridged ring compound" refers to a cyclic hydrocarbon in which any two rings in the compound share two carbon atoms that are not directly connected. It is divided into bicyclic hydrocarbons, tricyclic hydrocarbons, tetracyclic hydrocarbons, etc. according to the number of constituent rings.
[0073] The term "heterocyclyl" includes, but is not limited to, "heterocycloalkyl", "heterocycloalkenyl", "heterospirocyclyl", "heterobridged cyclyl", etc. "3-10 membered heterocyclyl" includes, but is not limited to, "3-10 membered heterocycloalkyl", "3-10 membered heterocycloalkenyl", "3-10 membered heterospirocyclyl", "3-10 membered heterobridged cyclyl", etc.
[0074] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I) which are located in Group VII of the Periodic Table of Elements.
[0075] The term "haloalkyl" refers to a linear or branched monovalent group formed by replacing at least one hydrogen atom in an alkyl group with a halogen atom, and does not contain unsaturation. 1-6 "Haloalkyl" refers to a haloalkyl group having 1 to 6 carbon atoms. 1-6 Non-limiting examples of haloalkyl include, but are not limited to, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, and the like.
[0076] The term "alkoxy" refers to an alkyl group attached to another moiety through an oxygen atom and contains no unsaturation. 1-6 "Alkoxy" refers to an alkoxy group having 1 to 6 carbon atoms. 1-6 Non-limiting examples of alkoxy groups include, but are not limited to, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCH2CH2CH2CH3, -OC(CH3)3, and the like.
[0077] The term "haloalkoxy" refers to a haloalkyl group attached to another moiety through an oxygen atom and contains no unsaturation. 1-6 The term "haloalkoxy" refers to a haloalkoxy group having 1 to 6 carbon atoms. 1-6 Non-limiting examples of haloalkoxy include, but are not limited to, -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -OCH2CH2CH2F, -OCH2CH2CHF2, -OCH2CH2CF3, and the like.
[0078] In the present application, "oxazabicyclo[3.2.1]octanyl" refers to a monovalent group obtained by losing a hydrogen atom from oxazabicyclo[3.2.1]octanyl. Non-limiting examples of oxazabicyclo[3.2.1]octanyl include, but are not limited to (8-oxo-3-azabicyclo[3.2.1]octanyl) and the like.
[0079] The term "hydroxy" refers to a "-OH" group. The term "amino" refers to a "-NH2" group. The term "nitro" refers to a "-NO2" group. The term "cyano" refers to a "-CN" group. The term "carbonyl" refers to a "-C(=O)-" group. The term "aldehyde" refers to a "-C(=O)H" group. The term "carboxyl" refers to a "-C(=O)OH" group.
[0080] The term "optionally" means that the event or situation described subsequently may or may not occur, and the description includes the occurrence of the event or situation and the non-occurrence of the event or situation. When referring to a group as "optionally substituted", this means that the group is substituted or unsubstituted. For example, a heterocyclic group is "optionally" substituted with a halogen, which means that the heterocyclic group may be unsubstituted, or may be monosubstituted, polysubstituted or fully substituted with a halogen atom. It will be understood by those skilled in the art that for any group containing one or more substituents, no substitution or substitution pattern that is sterically impossible to exist and / or cannot be synthesized will be introduced. The term "independently" means that when one or more substituents are selected from a number of possible groups, the groups corresponding to these substituents may be the same or different.
[0081] The term "room temperature" means that the temperature may be 10-40°C, or 10-30°C, such as 25°C.
[0082] In this application, the terms "include", "comprises", and "contains" and their equivalents should be understood as open, non-exclusive meanings, i.e., "including but not limited to", meaning that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be included. In this document, unless the context clearly dictates otherwise, singular terms encompass plural referents, and vice versa. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise.
[0083] Unless otherwise specified, in this article, the parameter values representing the amount of ingredients or physicochemical properties or reaction conditions, etc. should be understood to be modified by the term "about" in all cases. When the term "about" is used to describe the present application, the term "about" indicates the error value that exists, for example, it indicates a change within the range of ±5%, such as ±1% or ±0.1% of a particular value.
[0084] The term "subject" encompasses mammals, such as humans, non-human primates (eg, rhesus monkeys), pigs, cows, horses, sheep, dogs, rabbits, mice, and the like.
[0085] For the purpose of description and disclosure, all patents, patent applications and other publications are expressly incorporated herein by reference. These publications are provided only because they are disclosed prior to the filing date of the present application. All statements about the dates of these documents or the representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents.
[0086] [Compounds useful as PRMT5 inhibitors]
[0087] The present application provides a novel compound that can be used as a PRMT5 inhibitor or a pharmaceutically acceptable form thereof, such as a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label (e.g., deuterated substance) or prodrug thereof.
[0088] In one embodiment of the present application, the structure of the compound is as shown in Formula I:
[0089]
[0090] in:
[0091] represents a single bond or a double bond;
[0092] Every R 1 Each independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10Aryl and 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is optionally substituted with one or more halogen, cyano, hydroxyl, amino, nitro, C 1-6 Haloalkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl substituted;
[0093] Every R 2 Each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is optionally substituted with one or more halogen, cyano, hydroxyl, amino, nitro, C 1-6 Haloalkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl substituted;
[0094] Every R 3 are each independently selected from H, halogen, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 3-10 Cycloalkyl and 3-10 membered heterocyclic group;
[0095] Or, R 1 and R 3 Connected to each other to form a 5-10 membered heterocyclic group;
[0096] A is selected from 3-10 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl;
[0097] R 4 Selected from H, halogen, cyano, hydroxyl, nitro, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR 1 R 2 、-C(=O)R1 、-NHC(=O)R 1 、-SO2R 1 、-SOR 1 , C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, oxazabicyclo[3.2.1]octanyl, -C(=S)SR 6 and-P(=O)R 11 R 12 ; said C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR 1 R 2 、-C(=O)R 1 、-NHC(=O)R 1 、-SO2R 1 、-SOR 1 , C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, oxazabicyclo[3.2.1]octanyl, -C(=S)SR 6 or -P(=O)R 11 R 12 Optionally substituted with one or more substituents selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, halogen, hydroxyl, amino, cyano, nitro, =NH, =NR 3 、-C(=S)SR 6 、-(C 1-6 Alkylene)-OH, -(C 1-6 Alkylene)-NH2, C 1-6 Haloalkyl and -P(=O)R 11 R 12 ;
[0098] R 5 Selected from H, -P(=O)R 11 R 12 , -R a -P(=O)R 11 R 12 , -R a -C(=S)SR 6 and-C(=S)SR 6 ;and,
[0099] R 4 and R 5 Not at the same time hydrogen;
[0100] Every R 11 and R 12 Each independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, NH(R c )-(C 1-6 Alkylene)- and N(R c )(C 1-6 Alkyl)-(C 1-6 Alkylene)-, or, R 11 and R 12 are connected to each other to form a 5-10 membered heterocyclic group; 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, 5-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl is optionally substituted with one or more R c replace;
[0101] Every R c are each independently selected from H, halogen, O=, HN=, C 1-6 Alkoxy, (C 1-6 Alkyl)-N=, C 1-6 Alkyl, (C 1-6 alkyl)-C(=O)-, (C 1-6 Alkyl)-SO2-, (C 3-6 Cycloalkyl)-SO2-, (C 1-6 alkyl)-OC(=O)-, (C 1-6 alkyl)-O-(C 1-6 Alkylene)-, (C 1-6 alkyl)-O-(C 1-6 Alkylene)-C(=O)-, NH2-C(=O)-, (C 1-6 alkyl)-NH-C(=O)-, (C 1-6 Alkyl)2N-C(=O)-, NH2-(C 1-6 Alkylene)-C(=O)-, (C 1-6 alkyl)-NH-(C 1-6 Alkylene)-C(=O)-, (C 1-6 Alkyl)2N-(C 1-6 Alkylene)-C(=O)-, NH2-C(=O)-(C 1-6 Alkylene)-, (C 1-6 alkyl)-NH-C(=O)-(C 1-6Alkylene)-, (C 1-6 alkyl)2N-C(=O)-(C 1-6 Alkylene)-, C 3-6 Cycloalkyl, (C 3-6 Cycloalkyl)-C(=O)-, (C 3-6 Cycloalkyl)-(C 1-6 alkylene)-, 3-10 membered heterocyclic group, (3-10 membered heterocyclic group)-C(=O)-, (3-10 membered heterocyclic group)-(C 1-6 Alkylene)-, (C 6-10 Aryl)-(C 1-6 Alkylene)- and C substituted by one or more hydroxyl or cyano groups 1-6 Alkyl; when R c When it is not H, halogen or O=, R c optionally substituted with one or more halogens;
[0102] R a Selected from C 1-6 Alkylene, -(C 3-8 cycloalkyl)-(C=O)-, 3-10 membered heterocyclyl, 5-10 membered heteroaryl and C 6-10 Aryl; the 3-10 membered heterocyclic group, 5-10 membered heteroaryl or C 6-10 The aryl group is optionally substituted with one or more halogen, cyano, hydroxy, nitro, amino, aldehyde, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Haloalkoxy substitution;
[0103] Every R 6 Each independently selected from H, C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-(3-8 membered heterocyclic group), C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -(C 1-6 Alkylene)-OH, -(C 1-6 Alkylene)-NH2, -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-NH-(C 1-6 Alkyl), -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)NH(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)N(C 1-6 Alkyl)2, -SOR 1 and-SO2R 1 ;
[0104] X1 for CR 3 or N;
[0105] X2 for CR 3 or N;
[0106] X3 for CR 3 , C(R 3 )2. NR 3 , C=O or N;
[0107] X4 for CR 10 or N;
[0108] X5 for CR 9 or N;
[0109] R 7 is H or methyl;
[0110] R 8 is selected from H, halogen, alkynyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy and -(C 1-6 Alkylene)-NH2;
[0111] If present, R 9 is selected from H, halogen, alkynyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy and C 3-10 Cycloalkyl;
[0112] Or, if present, R 8 and R 9 Connect to each other to form C 3-10 Cycloalkenyl, 5-10 membered heterocyclyl or 5-10 membered heteroaryl; the 5-10 membered heterocyclyl or 5-10 membered heteroaryl each independently contains at least one N, O or S;
[0113] If present, R 10 is selected from H, amino, hydroxyl and carboxyl;
[0114] m is 0, 1, 2, 3 or 4;
[0115] Furthermore, the compound having the structure of Formula I satisfies the following conditions at the same time:
[0116] Condition 1: When R 5 is H, and R 1 and R 3 When they are not connected to each other to form a 5-10 membered heterocyclic group, X3 is not N;
[0117] Condition 2: When R 8 and R 9 When connected to form a 5-10 membered heterocyclic group, R 4 For H.
[0118] In one embodiment of the present application, R 1 It is a 5-10 membered heteroaryl group, preferably a 5-10 membered N-containing heteroaryl group, more preferably a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, an indolyl group or a quinolyl group, and further preferably a pyrimidinyl group.
[0119] In one embodiment of the present application, R 2 C 1-6 The alkyl group is preferably a methyl group, an ethyl group or a propyl group, and more preferably a methyl group.
[0120] In one embodiment of the present application, R 3 For H.
[0121] In one embodiment of the present application, R 1 and R 3 They are connected to each other to form a 5-10 membered heterocyclic group; preferably, the 5-10 membered heterocyclic group is a 5-10 membered heterocycloalkyl, preferably morpholinyl, thiomorpholinyl, 1,3-oxazinyl, 1,4-nitrogen phosphorus hexacyclyl, piperazinyl or piperidinyl, more preferably morpholinyl or thiomorpholinyl.
[0122] In one embodiment of the present application, A is a 5-14-membered heteroaryl, preferably a 5-14-membered N-containing heteroaryl, more preferably a 5-10-membered N-containing heteroaryl, further preferably a pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl or quinolyl, and further preferably a pyridyl.
[0123] In one embodiment of the present application, R 4 H or C 1-6 Halogenated alkyl.
[0124] In one embodiment of the present application, R 5 H, -P(=O)R 11 R 12 or -R a -C(=S)SR 6 , preferably, R 4 and R 5 Not H at the same time.
[0125] In one embodiment of the present application, R 4 For H, R 5 -P(=O)R 11 R 12 or -R a -C(=S)SR 6 .
[0126] In one embodiment of the present application, R 4 For H, R 5 For-R a -C(=S)SR 6 .
[0127] In one embodiment of the present application, R 4 C 1-6 Haloalkyl, R 5 For H.
[0128] In one embodiment of the present application, R 11 and R 12 Each independently is C 1-6 Alkyl (preferably methyl, ethyl, propyl or isopropyl), C 2-6 Alkenyl (preferably vinyl or allyl), C 3-10 Cycloalkyl (preferably cyclopropyl), C 6-10 Aryl (preferably phenyl or naphthyl) or 5-10 membered heteroaryl (preferably thiazolyl), or R 11 and R 12 Connected to form a 5-10 membered heterocyclic group (preferably ); said C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 5-10 membered heterocyclic group is optionally substituted by one or more R c replace.
[0129] In one embodiment of the present application, R c For halogen, C 1-6 Alkyl, C 1-6 Alkoxy or (C 3-10cycloalkyl)-C(=O)-, preferably fluorine, chlorine, methyl, ethyl, propyl, methoxy, cyclopropanyl-C(=O)-, cyclobutanyl-C(=O)-, cyclopentanyl-C(=O)- or cyclohexanyl-C(=O)-, more preferably fluorine, chlorine, methyl, methoxy or cyclopropanyl-C(=O)-.
[0130] In one embodiment of the present application, R a is a 3-10 membered heterocyclyl (preferably a 3-10 membered heterocycloalkyl, a 3-10 membered heterocycloalkenyl or a 3-10 membered heterospirocyclyl); the 3-10 membered heterocycloalkyl, the 3-10 membered heterocycloalkenyl or the 3-10 membered heterospirocyclyl is optionally substituted by one or more hydroxyl groups; the 3-10 membered heterocycloalkyl may be a piperidinyl, a piperazinyl or an azacycloheptyl, the 3-10 membered heterocycloalkenyl may be The 3-10 membered heterospirocyclic group may be a 2,6-diazaspiro[3.3]heptyl group.
[0131] In one embodiment of the present application, R 6 C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-(3-8 membered heterocyclic group), C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)O(C 1-6 alkyl) or -(C 1-6 Alkylene)-C(=O)N(C 1-6 In one embodiment of the present application, the 3-10 membered heterocyclic group may be a 3-8 membered O- or N-containing heterocyclic group, or a 4-6 membered O- or N-containing heterocyclic group, such as an oxetane group, a tetrahydropyrrolyl group, a morpholinyl group or a piperidinyl group; In one embodiment of the present application, the -(C 1-6 The 3-8 membered heterocyclic group in (alkylene)-(3-8 membered heterocyclic group) may be a 3-8 membered O- or N-containing heterocyclic group, or a 4-6 membered O- or N-containing heterocyclic group, such as oxetanyl, tetrahydropyrrolyl, morpholinyl or piperidinyl.
[0132] In one embodiment of the present application, R 6 It is methyl, ethyl or propyl, preferably methyl.
[0133] In one embodiment of the present application, X1 is CR 3 or N, where R 3 is H or halogen, preferably H.
[0134] In one embodiment of the present application, X2 is CR 3 , where R 3 For H.
[0135] In one embodiment of the present application, X3 is C═O or N, preferably N.
[0136] In one embodiment of the present application, X4 is CR 10 or N, where R 10 It is H or amino, preferably amino.
[0137] In one embodiment of the present application, X5 is CR 9 or N, where R 9 H, halogen, C 1-6 Alkyl or C 3-10 Cycloalkyl, preferably H or halogen.
[0138] In one embodiment of the present application, R 7 For H.
[0139] In one embodiment of the present application, R 8 H or -(C 1-6 Alkylene)-NH2, preferably H.
[0140] In one embodiment of the present application, R 9 is H, halogen or C 1-6 Alkyl, preferably H.
[0141] In one embodiment of the present application, R 8 and R 9 Connect to each other to form C 3-10 Cycloalkenyl, 5-10 membered heterocyclic group or 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclic group or the 5-10 membered heteroaryl each independently contains at least one O, N or S; wherein the C 3-10 The cycloalkenyl group may be The 5-10 membered heterocyclic group can be The 5-10 membered heteroaryl group can be
[0142] In one embodiment of the present application, R 10 It is H or amino, preferably amino.
[0143] In one embodiment of the present application, m is 0.
[0144] In one embodiment of the present application, the structure of the compound is as shown in Formula I-1:
[0145]
[0146] Among them: X1, X3~X5, R1~R5, R7~R8 and As defined in Formula I.
[0147] In one embodiment of the present application, the structure of the compound is as shown in Formula I-2:
[0148]
[0149] Among them: X1, X3~X5, R1~R5, R7~R8 and As defined in Formula I.
[0150] In one embodiment of the present application, the structure of the compound is as shown in Formula I-3A:
[0151]
[0152] Among them: X1, R1~R5 and R7~R 10 As defined in Formula I.
[0153] In one embodiment of the present application, the structure of the compound is as shown in Formula I-3B:
[0154]
[0155] Among them: R1~R5, R7, R8 and R 10 As defined in Formula I.
[0156] In one embodiment of the present application, the structure of the compound is as shown in Formula I-4A1:
[0157]
[0158] Wherein: X1, R3-R5 and R7-R9 are as defined in Formula I.
[0159] In some preferred embodiments, in the compound shown in Formula I-4A1, X1 is CR 3 , each R 3 Each independently selected from H or C 1-3 Alkyl; R 4 Select from H or C 1-3 Alkyl; R 5 Selected from -R a -C(=S)SR 6 , R ais selected from a 5-7 membered heterocyclic group (e.g. a 5-7 membered heterocycloalkenyl group) or a 5-7 membered heteroaryl group, R 6 Each independently selected from H, C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-NH-(C 1-6 Alkyl), -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-NH2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-(4-6 membered heterocyclic group), the heterocyclic group contains 1-3 (preferably 1-2) N or O atoms; R 7 and R 8 are each independently selected from H or methyl; R 9 Select from H or C 1-6 alkyl.
[0160] In one embodiment of the present application, the structure of the compound is as shown in Formula I-4A 1’ As shown:
[0161] Among them, R 3 Select from H or C 1-3 Alkyl (preferably H), R 6 Each independently selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 alkylene)-(4-6 membered heterocyclic group), wherein the heterocyclic group contains 1-2 N or O atoms; R 7 and R 8 Each is independently selected from H or methyl (preferably H); R 9 Select from H or C 1-3 alkyl.
[0162] In one embodiment of the present application, the structure of the compound is shown in Formula I-4A2:
[0163]
[0164] Wherein: X1, R3-R5 and R7 are as defined in Formula I.
[0165] In one embodiment of the present application, the structure of the compound is shown in Formula I-4A3:
[0166]
[0167] Wherein: X1, R3-R5 and R7 are as defined in Formula I.
[0168] In one embodiment of the present application, the structure of the compound is shown in Formula I-4A4:
[0169]
[0170] Wherein: R4-R5 and R7-R9 are as defined in Formula I.
[0171] In some embodiments, in the compound of formula I,
[0172] represents a double bond;
[0173] R 1 Each independently is C 6-10 Aryl or a 5-10 membered heteroaryl group containing 1-3 N, O or S atoms (preferably N atoms); preferably, R 1 Each is independently a 5-7 membered heteroaryl group containing 1-2 N atoms;
[0174] R 2 Each independently is C 1-6 Alkyl; preferably C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl, C1 alkyl, C2 alkyl or C3 alkyl;
[0175] R 3 Each independently is H;
[0176] Or, R 1 and R 3 are connected to each other to form a 5-10 membered heterocycloalkyl group containing 1-3 N, O or S atoms (preferably N or O atoms); preferably, R 1 and R 3 Connected to each other to form a 5-7 membered heterocycloalkyl group containing 1-2 N, O or S atoms (preferably N or O atoms);
[0177] A is C 6-10 Aryl or a 5-10 membered heteroaryl containing 1-3 N, O or S atoms (preferably N atoms); preferably, A is a 5-7 membered heteroaryl containing 1-2 N atoms;
[0178] R 4 H, C 1-6Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-10 Cycloalkyl, or a 3-10 membered heterocyclic group containing 1-3 N, O or S atoms (preferably N atoms), wherein the C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl are optionally substituted by one or more substituents selected from halogen and -C(=S)SR 6 Preferably, R 4 C 1-6 Haloalkyl, 5-7 membered heterocycloalkyl containing 1-3 N atoms (preferably 1-2 N atoms), or 5-7 membered heterocycloalkenyl containing 1-3 N atoms (preferably 1-2 N atoms);
[0179] R 5 H, or -R a -C(=S)SR 6 ; and, R 4 and R 5 Not at the same time H;
[0180] R a is a 3-10 membered heterocyclic group containing 1-3 N, O or S atoms (preferably N atoms), preferably, R a is a 5-7 membered heterocycloalkyl group containing 1-3 N atoms (preferably 1-2 N atoms), or a 5-7 membered heterocycloalkenyl group containing 1-3 N atoms (preferably 1-2 N atoms);
[0181] R 6 Each independently selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 alkylene)-(3-8 membered heterocyclic group), 3-10 membered heterocyclic group, -(C 1-6 Alkylene)-NH-(C 1-6 Alkyl), -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-C(=O)O(C 1-6 alkyl), the heterocyclic group contains 1-3 N, O or S atoms; preferably, R 6 Each independently selected from C 1-6 Alkyl, C 1-6Deuterated alkyl, -(C 1-6 alkylene)-(4-7 membered heterocyclic group), 3-5 membered heterocyclic group, -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), the heterocyclic group contains 1-3 (preferably 1-2) N or O atoms;
[0182] X1 is CH;
[0183] X2 is CH;
[0184] X3 is N;
[0185] X4 for CR 10 ;
[0186] X5 for CR 9 ;
[0187] R 7 is H;
[0188] R 8 is H;
[0189] R 9 is H or halogen;
[0190] R 10 is H or amino.
[0191] In some preferred embodiments, in the compound of formula I,
[0192] represents a double bond;
[0193] R 1 is pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, preferably pyrimidinyl;
[0194] R 2 C 1-6 Alkyl; preferably C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl, C1 alkyl, C2 alkyl or C3 alkyl;
[0195] R 3 is H;
[0196] Or, R 1 and R 3Connected to each other to form morpholinyl, thiomorpholinyl, 1,3-oxazinyl, 1,4-nitrogen phosphorus hexacyclyl, piperazinyl or piperidinyl, preferably morpholinyl or thiomorpholinyl;
[0197] A is pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, preferably pyridyl;
[0198] R 4 For H, R 5 For-R a -C(=S)SR 6 ; or R 4 C 1-6 Haloalkyl (e.g. C 1-5 Haloalkyl, C 1-4 Haloalkyl or C 1-3 haloalkyl), R 5 is H;
[0199] R a For piperidinyl, piperazinyl,
[0200] R 6 Each independently selected from C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl), C 1-6 Deuterated alkyl (e.g. C 1-5 Deuterated alkyl, C 1-4 Deuterated alkyl or C 1-3 Deuterated alkyl), -(C 1-6 alkylene)-(5-6 membered heterocyclic group), 4-5 membered heterocyclic group, -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), the heterocyclic group contains 1-2 N or O atoms;
[0201] X1 is CH;
[0202] X2 is CH;
[0203] X3 is N;
[0204] X4 for CR 10 ;
[0205] X5 for CR 9 ;
[0206] R 7 is H;
[0207] R 8 is H;
[0208] R 9 is H or halogen;
[0209] R 10 It is amino.
[0210] In one embodiment of the present application, the structure of the compound is shown in Formula I-4A5:
[0211]
[0212] Wherein: R4-R5 and R7 are as defined in Formula I.
[0213] In one embodiment of the present application, the structure of the compound is shown in Formula I-4A6:
[0214]
[0215] Wherein: R4-R5 and R7 are as defined in Formula I.
[0216] In one embodiment of the present application, the structure of the compound is as shown in Formula I-4B:
[0217]
[0218] Wherein: R3-R5 and R7-R8 are as defined in Formula I.
[0219] Specifically, the small molecule compounds used as PRMT5 inhibitors of the present application include but are not limited to the following compounds:
[0220]
[0221]
[0222]
[0223]
[0224] [Drug composition]
[0225] The term "pharmaceutical composition" refers to a composition that can be used as a medicament, which comprises a pharmaceutically active ingredient (API) and optionally one or more pharmaceutically acceptable carriers.
[0226] The term "pharmaceutically acceptable carrier" refers to a pharmaceutical excipient that is compatible with the active ingredient of the drug and is harmless to the subject, including but not limited to one or more of a diluent (or filler), a binder, a disintegrant, a lubricant, a wetting agent, a thickener, a glidant, a flavoring agent, an olfactory agent, a preservative, an antioxidant, a pH adjuster, a solvent, a cosolvent, a surfactant, a light-shielding agent (opacifying agent), etc.
[0227] The present application provides a pharmaceutical composition comprising the above-mentioned compound or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof.
[0228] In one embodiment of the present application, the above-mentioned pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.
[0229] [Drug preparations]
[0230] The term "pharmaceutical preparation" refers to a finished drug prepared in a certain form for use by patients.
[0231] The present application provides a pharmaceutical preparation, which is prepared from the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug or the above-mentioned pharmaceutical composition.
[0232] In one embodiment of the present application, the above-mentioned pharmaceutical preparation can be a solid preparation for oral administration, including but not limited to pharmaceutically acceptable capsules, tablets, pills, powders, granules, etc. The solid preparation can be coated or microencapsulated with a coating or shell material (such as an enteric coating or other materials known in the art). The solid preparation can contain an opacifying agent, and the active ingredient therein can be released in a certain part of the digestive tract in a delayed manner. Examples of embedding components that can be adopted are polymeric substances and wax substances. In addition, the active ingredient can also form a microcapsule form with one or more of the above-mentioned carriers.
[0233] In another embodiment of the present application, the above-mentioned pharmaceutical preparation may be a liquid dosage form for oral administration, including but not limited to pharmaceutically acceptable emulsions, solutions, suspensions, syrups, tinctures, etc.
[0234] In another embodiment of the present application, the above-mentioned pharmaceutical preparations may be dosage forms for parenteral injection, including but not limited to physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions and dispersions.
[0235] In another embodiment of the present application, the above-mentioned pharmaceutical preparation may be a dosage form for topical administration, including but not limited to ointments, powders, suppositories, drops, sprays, inhalants, and the like.
[0236] [Medical Use]
[0237] Whether it is the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug, or the above-mentioned pharmaceutical composition, or the above-mentioned pharmaceutical preparation, it can show inhibitory activity on PRMT5. Therefore, the present application provides the use of the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation in the preparation of a drug for preventing and / or treating a disease mediated at least in part by PRMT5.
[0238] The present application also provides the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation, which is used as a drug (especially PRMT5 inhibitor) or for preventing and / or treating diseases at least partially mediated by PRMT5.
[0239] The present application also provides the above-mentioned compounds or their pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, tautomers, cis-trans isomers, isotope labels or prodrugs, or the above-mentioned pharmaceutical compositions, or the above-mentioned pharmaceutical preparations for preventing and / or treating diseases at least partially mediated by PRMT5.
[0240] The present application also provides a method for preventing and / or treating a disease mediated at least in part by PRMT5, which includes applying the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation to an individual in need thereof. In this article, the preventive and / or therapeutic effective amount refers to an amount sufficient to prevent, improve, inhibit, postpone, slow down the progression of a disease or related symptoms mediated at least in part by PRMT5, which can be determined by a clinician according to the severity of the disease, the patient's physical condition, age, sex, weight, etc., and can be administered by conventional routes of administration in the art. For example, the compound described in the present application or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation can be administered by parenteral, oral, subcutaneous, intravenous, intraperitoneal and other routes.
[0241] In one embodiment of the present application, the above-mentioned disease at least partially mediated by PRMT5 is cancer, cardiovascular disease or myelofibrosis. In a specific embodiment of the present application, the above-mentioned disease at least partially mediated by PRMT5 is cancer or cardiovascular disease. The term "cancer" refers to a cell disorder characterized by uncontrolled or dysregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissues and / or the ability to establish new growth at ectopic sites. Non-limiting examples of cancer include, but are not limited to, glioblastoma, melanoma, blood tumors (such as leukemia, lymphoma and multiple myeloma), bladder urothelial carcinoma, colorectal cancer, lung cancer, gastric cancer, ovarian cancer, breast cancer, cervical cancer, squamous cell carcinoma, brain cancer, prostate cancer and myelodysplastic syndrome. The term "cardiovascular disease" is also called circulatory system disease, which is a series of diseases involving the circulatory system. The circulatory system refers to the organs and tissues that transport blood in the human body, mainly including the heart, blood vessels (arteries, veins, capillaries), which can be subdivided into acute and chronic, and are generally related to arteriosclerosis. These diseases have similar causes, pathogenesis and treatment methods. Non-limiting examples of cardiovascular diseases include, but are not limited to, cardiac hypertrophy, heart failure, and cardiac arrhythmias.
[0242] [Combination medication]
[0243] The present application provides a drug combination, which comprises the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation, and at least one additional therapeutic agent.
[0244] In one embodiment of the present application, the above-mentioned compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation can be administered alone or in combination with other therapeutic agents. The combined therapy can be achieved by administering different therapeutic agents simultaneously, sequentially or separately.
[0245] [Abbreviation and full name]
[0246] In this manual, the English abbreviations and their corresponding Chinese full names are shown in the following table:
[0247]
[0248]
[0249] Example
[0250] The embodiments of the present application will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present application and should not be considered as limiting the scope of the present application. In the examples, if specific conditions are not specified, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0251] Example 1: Preparation of Compound 1
[0252] Synthesis of compound 1-1:
[0253]
[0254] Weigh diethyl cyanomethylphosphonate (7 g, 1.0 equiv.) and place it in a reaction bottle, add anhydrous tetrahydrofuran and stir to dissolve, replace nitrogen three times, slowly drop LiHMDS tetrahydrofuran solution (1 M, 1.1 equiv.) into the reaction bottle at 0°C, react at 0°C for 30 minutes, then cool to -78°C, add NBS (1.2 equiv.), then slowly warm the reaction system to -10°C, and react at this temperature for 5 hours. After the reaction is completed by TLC monitoring, dilute hydrochloric acid (1.5 M) is added to quench the reaction, tetrahydrofuran is removed under reduced pressure, and the remaining mixture is extracted 3 times with ethyl acetate, the organic phases are combined and concentrated under reduced pressure to obtain a crude product, which is purified by silica gel column chromatography (eluent PE: EA = 3: 1-2: 1) to obtain compound 1-1a (6.57 g, reddish brown oily liquid).
[0255] Weigh sodium hydride (2.5 equiv.) in a dry reaction bottle, replace nitrogen, add dry tetrahydrofuran at 0°C, stir evenly, dissolve compound 1-1a (2.0 equiv.) in dry tetrahydrofuran and slowly drop it into the reaction bottle, keep 0°C for reaction for 30 minutes, then weigh 4-amino-3-formylbenzoic acid methyl ester (2g, 1.0 equiv.) and dissolve it in dry tetrahydrofuran and slowly drop it into the reaction system, warm the reaction system to room temperature, and react for 5 hours. After the reaction is completed, add water to quench, extract with ethyl acetate 3 times, combine the organic phases and concentrate under reduced pressure to obtain a crude product, dry load, and purify by silica gel column chromatography (PE:EA=3:1-1:1) to obtain compound 1-1b (2.1 g, yellow solid). MS: m / z 281.0[M+H] + .
[0256] Weigh compound 1-1b (2.0 g, 1.0 equiv.) and place it in a reaction bottle, add palladium carbon (0.3 wt equiv.) and methanol in turn, replace the hydrogen, and react at room temperature for 3 hours. After the reaction is completed, filter, dry the filtrate and concentrate under reduced pressure to obtain compound 1-1c (1.8 g, yellow solid). MS: m / z 202.8 [M+H]+ .
[0257] Weigh compound 1-1c (1.8 g, 1.0 equiv.) and place it in a reaction bottle, add isopropanol: water = 1:1, sodium hydroxide (4.0 equiv.) in sequence, and react at room temperature for 3 hours. After the reaction is completed, concentrate under reduced pressure, add 1M hydrochloric acid dropwise to the reaction solution until a large amount of precipitate is generated, filter, wash the filter cake with water, and dry the filter cake to obtain compound 1-1 (1.52 g, light yellow solid). MS: m / z 188.8 [M+H] + .
[0258] Synthesis of compound 1-2:
[0259]
[0260] Weigh 2-aminomethyl-5-bromopyridine (2 g, 1.0 equiv.) and place it in a reaction bottle, add dichloromethane, 2-acetylpyrimidine (1.15 equiv.) and potassium acetate (1.30 equiv.) in sequence, react at room temperature for 30 minutes, then slowly add sodium triacetoxyborohydride (1.20 equiv.), and continue to react at room temperature for 5 hours. After the reaction is completed, wash the reaction mixture with water, separate the liquids, and extract the aqueous phase with dichloromethane three times. After TLC confirms that there is no product remaining in the aqueous phase, combine the organic phases and concentrate to obtain a crude product, dry-load, and purify by silica gel column chromatography (PE: EA = 2: 1-0: 1) to obtain compound 1-2 (1.91 g, yellow oil). MS: m / z 292.8 [M+H] + .
[0261] Synthesis of compound 1:
[0262]
[0263] Weigh compound 1-2 (0.5 g, 1.0 equiv.) and place it in a microwave reaction tube, add 1,4-dioxane, dimethylphosphine oxide (2.0 equiv.), tripotassium phosphate (3.0 equiv.), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (0.06 equiv.) and Pd2(dba)3 (0.03 equiv.) in sequence, replace nitrogen, and microwave at 135°C for 2 hours. After the reaction is completed, filter and concentrate the filtrate to obtain a crude product, which is purified by silica gel column chromatography (DCM:MeOH=15:1-10:1) to obtain compound 1a (0.37 g, brown liquid). MS: m / z 291.0 [M+H] + .
[0264] Weigh compound 1a (0.2 g, 1.0 equiv.) and place it in a reaction bottle, add DMF, compound 1-1 (1.2 equiv.), tripyrrolidinophosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.) in sequence, and react at room temperature for 4 hours. After the reaction is completed, pour the reaction solution into saturated brine, extract with ethyl acetate three times, combine the organic phases and concentrate under reduced pressure to obtain a crude product, separate and purify to obtain compound 1 (0.17 g, white solid). MS: m / z 461.0 [M+H] + .
[0265] Intermediate Preparation Example 1: Preparation of Compounds S-2, S-8 to S-17
[0266] Preparation of phosphine oxide S-2:
[0267]
[0268] Compound S-2a (0.78 mL, 5.0 mmol, 1.0 equiv.) and 12 mL Et2O were added to a dry round-bottom flask, and then anhydrous ethanol (7.3 mL, 12.5 mmol, 2.5 equiv.) was slowly added dropwise to the reaction system and reacted at room temperature for 2 hours. The solvent was concentrated under reduced pressure to obtain a crude product, namely compound S-2b. MS: m / z 171.1 [M+H] + .
[0269] Under nitrogen protection, MeMgBr was added to a clean, dry reaction bottle and cooled to -78°C. Compound S-2b was dissolved in anhydrous THF and slowly added dropwise (more than 30 min) to the reaction bottle. After the addition was complete, the reaction system was heated to room temperature and reacted for 2 hours. Saturated ammonium chloride solution was added to the reaction system to quench the reaction, and then extracted three times with DCM. The organic phases were combined, dried, concentrated under reduced pressure, and chromatographed on a silica gel column to obtain the product, i.e., compound S-2. MS: m / z 141.0 [M+H] + .
[0270] Preparation of phosphine oxide S-8:
[0271]
[0272] Except that S-2a was replaced by S-8a, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-8, MS: m / z 159.0 [M+H] + .
[0273] Preparation of phosphine oxide S-9:
[0274]
[0275] Except that S-2a was replaced by S-9a, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-9, MS: m / z 147.0 [M+H] + .
[0276] Preparation of phosphine oxide S-10:
[0277]
[0278] Except that S-2a was replaced by S-10a, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-10, MS: m / z 155.0 [M+H] + .
[0279] Preparation of phosphine oxide S-11:
[0280]
[0281] Except that methylmagnesium bromide was replaced by isopropylmagnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-11, MS: m / z 169.1 [M+H] + .
[0282] Preparation of phosphine oxide S-12:
[0283]
[0284] Except that methylmagnesium bromide was replaced by cyclopropylmagnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-12, MS: m / z 167.1 [M+H] + .
[0285] Preparation of phosphine oxide S-13:
[0286]
[0287] Except that methylmagnesium bromide was replaced by allylmagnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-13, MS: m / z 167.0 [M+H] + .
[0288] Preparation of phosphine oxide S-14:
[0289]
[0290] Except that methylmagnesium bromide was replaced by alkenylmagnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-14, MS: m / z 153.0 [M+H] + .
[0291] Preparation of phosphine oxide S-15:
[0292]
[0293] Except that methylmagnesium bromide was replaced by phenylmagnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-15, MS: m / z 203.0 [M+H] + .
[0294] Preparation of phosphine oxide S-16:
[0295]
[0296] Except that methyl magnesium bromide was replaced by 3-methoxyphenyl magnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-16, MS: m / z 233.1 [M+H] + .
[0297] Preparation of phosphine oxide S-17:
[0298]
[0299] Except that methylmagnesium bromide was replaced by 4-chlorophenylmagnesium bromide, the other conditions were the same as those for the preparation of compound S-2 to obtain compound S-17, MS: m / z 237.0 [M+H] + .
[0300] Example 2: Preparation of Compound 2
[0301]
[0302] Except that dimethylphosphine oxide was replaced by S-2, the other conditions were the same as those for the preparation of compound 1 to obtain compound 2, MS: m / z 523.2 [M+H] + .
[0303] Example 3: Preparation of Compound 3
[0304]
[0305] Except that dimethylphosphine oxide was replaced by S-3, the other conditions were the same as those for the preparation of compound 1 to obtain compound 3, MS: m / z 487.2 [M+H] + .
[0306] Example 4: Preparation of Compound 4
[0307]
[0308] Add ammonium hypophosphite (14g) to a 250mL three-necked flask, add hexamethyldisilazane (55g) dropwise, complete the addition, heat the reaction solution to 120°C under nitrogen protection for 4 hours, add bis(2-bromoethyl)ether (39g) dropwise to the reaction flask, and keep the temperature for 4 hours. After the reaction is completed, cool to 0°C, add anhydrous ethanol (75mL) dropwise thereto, complete the addition, and reflux for 1 hour. Stop the reaction, cool the reaction solution to room temperature, filter with suction, wash the filter cake with dichloromethane, and concentrate the filtrate to obtain a crude compound 4a, which is directly used in the next step without purification.
[0309] Add crude compound 4a (1.0 g) and dichloromethane (20 mL) to a 25 mL three-necked flask, cool to 0 ° C under nitrogen protection, add oxalyl chloride (1.58 g) dropwise to the reaction flask, warm to room temperature after the addition is complete, and stir overnight. After the reaction is complete, the reaction solution is concentrated to dryness, and the residue is dissolved in toluene (10 mL) and concentrated to dryness to obtain crude compound 4b, which is directly used in the next step without purification.
[0310] Under nitrogen protection, a 1M toluene solution of diisobutylaluminum hydride (6.48 mL) was slowly added to a -70°C solution of compound 4b (1.88 g dissolved in 15 mL of dichloromethane). After the addition was completed and the reaction was allowed to proceed for 2 hours, methanol (3 mL) was added and the reaction was allowed to proceed for 5 minutes. The reaction solution was transferred to an ice-water bath and continued to be stirred until the reaction solution temperature reached 0°C. A 10% aqueous acetic acid solution (10 mL) was added thereto and the solution was stirred at room temperature for 10 minutes. The resulting solution was separated, the aqueous phase was extracted with dichloromethane, the organic phases were combined, the organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 4c, which was directly used in the next step without purification.
[0311] Weigh compound 1-2 (0.5 g, 1.0 equiv.) and place it in a microwave reaction tube, add 1,4-dioxane, compound 4c (2.0 equiv.), tripotassium phosphate (3.0 equiv.), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (0.06 equiv.) and Pd2(dba)3 (0.03 equiv.) in sequence, replace nitrogen, and microwave at 135°C for 2 hours. After the reaction is completed, filter and concentrate the filtrate to obtain a crude product, which is purified by silica gel column chromatography (DCM:MeOH=15:1-10:1) to obtain compound 4d. MS: m / z333.1[M+H] + .
[0312] Weigh compound 4d (0.2 g, 1.0 equiv.) and place it in a reaction bottle, add DMF, compound 1-1 (1.2 equiv.), tripyrrolidinophosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.) in sequence, and react at room temperature for 4 hours. After the reaction is completed, pour the reaction solution into saturated brine, extract with ethyl acetate three times, combine the organic phases and concentrate under reduced pressure to obtain a crude product, separate and purify to obtain compound 4. MS: m / z 503.2 [M+H] + .
[0313] Example 5: Preparation of Compound 5
[0314]
[0315] Compound 5a was synthesized according to references (Maier. L. Helv. Chim. Acta 1971, 54, 275 and Dunne, J. Org. Chem., 2005, 70, 10803-10809).
[0316] Weigh compound 5a (2.0 g) and dichloromethane into a round-bottom flask, cool the reaction system to 0°C, then slowly drop LiAlH4 (3.16 mL, 2M in THF) into the reaction system, stir for 45 minutes, then slowly drop water (3.0 mL), 15% NaOH (3.0 mL) and water (9.0 mL) in sequence. Continue stirring for 1 hour after the addition is complete, then filter, wash the filter cake with THF, concentrate the filtrate to obtain a crude product, and purify the crude product by silica gel column chromatography to obtain compound 5b. MS: m / z 210.1 [M+H] + .
[0317] Weigh compound 1-2 (0.5 g, 1.0 equiv.) and place it in a microwave reaction tube, add 1,4-dioxane, compound 5b (2.0 equiv.), tripotassium phosphate (3.0 equiv.), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (0.06 equiv.) and Pd2(dba)3 (0.03 equiv.) in sequence, replace nitrogen, and microwave at 135°C for 2 hours. After the reaction is completed, filter and concentrate the filtrate to obtain a crude product, which is purified by silica gel column chromatography (DCM:MeOH=15:1-10:1) to obtain compound 5c. MS: m / z422.2[M+H] + .
[0318] Weigh compound 5c (0.2 g, 1.0 equiv.) and place it in a reaction bottle, then add DMF, compound 1-1 (1.2 equiv.), tripyrrolidinophosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.) in sequence, and react at room temperature for 4 hours. After the reaction is completed, pour the reaction solution into saturated brine, extract with ethyl acetate three times, combine the organic phases and concentrate under reduced pressure to obtain a crude product, which is separated and purified to obtain compound 5d. MS: m / z 592.3 [M+H] + .
[0319] A mixture of compound 5d, 4M HCl solution of 1,4-dioxane and Pd / C (30% wt) in methanol was hydrogenated overnight in hydrogen. The reaction mixture was filtered through celite, washed with methanol, and the filtrate was concentrated and lyophilized to obtain compound 5 in the form of hydrochloride. MS: m / z 502.2 [M+H] + .
[0320] Example 6: Preparation of Compound 6
[0321]
[0322] Compound 5d (1.0 equiv.), Boc2O (1.5 equiv.), DIEA (2.0 equiv.) and dichloromethane were added to a round-bottom flask in sequence and stirred at room temperature for 3 hours. After TLC monitoring, the raw materials were consumed, and the system was concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography to obtain compound 6a. MS: m / z 692.3 [M+H] + .
[0323] A mixture of compound 6a, 4M HCl solution of 1,4-dioxane and Pd / C (30% wt) in methanol was hydrogenated overnight in hydrogen. The reaction mixture was filtered through celite, washed with methanol, and the filtrate was concentrated and lyophilized to give compound 6b in the form of hydrochloride. MS: m / z 602.3 [M+H] + .
[0324] Compound 6b was dissolved in dichloromethane, triethylamine (2.0 equiv.) was added, and iodomethane was slowly added dropwise. After the addition was completed, the reaction was continued until the raw material 6b was completely consumed. The system was concentrated to dryness, and then purified by silica gel column chromatography to obtain compound 6c. MS: m / z 616.3 [M+H] + .
[0325] Weigh compound 6c (1.0 equiv.) into a reaction bottle, dissolve it with dichloromethane, add trifluoroacetic acid (3.0 equiv.), and stir at room temperature. Use TLC to monitor the progress of the reaction every 2 hours. If the reaction is not completed, add trifluoroacetic acid. After the reaction is completed, concentrate under reduced pressure, dissolve it with dichloromethane and concentrate under reduced pressure to remove excess trifluoroacetic acid, and then purify it by silica gel column chromatography to obtain compound 6. MS: m / z 516.2 [M+H] + .
[0326] Example 7: Preparation of Compound 7
[0327]
[0328] Except that iodomethane was replaced by cyclopropylcarbonyl chloride, the other conditions were the same as those for the preparation of compound 6 to obtain compound 7, MS: m / z 570.2 [M+H] + .
[0329] Example 8: Preparation of Compound 8
[0330]
[0331] Except that dimethylphosphine oxide was replaced by S-8, the other conditions were the same as those for the preparation of compound 1 to obtain compound 8, MS: m / z 541.2 [M+H] + .
[0332] Example 9: Preparation of Compound 9
[0333]
[0334] Except that dimethylphosphine oxide was replaced by S-9, the other conditions were the same as those for the preparation of compound 1 to obtain compound 9, MS: m / z 529.2 [M+H] + .
[0335] Example 10: Preparation of Compound 10
[0336]
[0337] Except that dimethylphosphine oxide was replaced by S-10, the other conditions were the same as those for the preparation of compound 1 to obtain compound 10, MS: m / z 537.2 [M+H] + .
[0338] Example 11: Preparation of Compound 11
[0339]
[0340] Except that dimethylphosphine oxide was replaced by S-11, the other conditions were the same as those for the preparation of compound 1 to obtain compound 11, MS: m / z 550.2 [M+H] + .
[0341] Example 12: Preparation of Compound 12
[0342]
[0343] Except that dimethylphosphine oxide was replaced by S-12, the other conditions were the same as those for the preparation of compound 1 to obtain compound 12, MS: m / z 549.2 [M+H] + .
[0344] Example 13: Preparation of Compound 13
[0345]
[0346] Except that dimethylphosphine oxide was replaced by S-13, the other conditions were the same as those for the preparation of compound 1 to obtain compound 13, MS: m / z 549.2 [M+H] + .
[0347] Example 14: Preparation of Compound 14
[0348]
[0349] Except that dimethylphosphine oxide was replaced by S-14, the other conditions were the same as those for the preparation of compound 1 to obtain compound 14, MS: m / z 535.2 [M+H] + .
[0350] Example 15: Preparation of Compound 15
[0351]
[0352] Except that dimethylphosphine oxide was replaced by S-15, the other conditions were the same as those for the preparation of compound 1 to obtain compound 15, MS: m / z 585.2 [M+H] + .
[0353] Example 16: Preparation of Compound 16
[0354]
[0355] Except that dimethylphosphine oxide was replaced by S-16, the other conditions were the same as those for the preparation of compound 1 to obtain compound 16, MS: m / z 615.2 [M+H] + .
[0356] Example 17: Preparation of Compound 17
[0357]
[0358] Except that dimethylphosphine oxide was replaced by S-17, the other conditions were the same as those for the preparation of compound 1 to obtain compound 17, MS: m / z 619.2 [M+H] + .
[0359] Example 18: Preparation of Compound 18
[0360]
[0361]
[0362] Weigh compound 1-2 (200 mg, 1.0 equiv.) and place it in a reaction bottle, add dioxane: ethanol: water = 3: 1: 1, stir and dissolve, then add N-Boc-tetrahydropyridine-4-boric acid pinacol ester (1.2 equiv.), tripotassium phosphate (3.0 equiv.) and Pd(dppf)Cl2 (0.1 equiv.) in sequence, protect with nitrogen, heat under reflux at 100°C, and react for 5 hours. After the reaction is completed, filter the reaction mixture, wash the filter cake with ethyl acetate, concentrate the filtrate under reduced pressure, and purify by silica gel column chromatography (dichloromethane: methanol = 15: 1-10: 1) to obtain compound 18a (245 mg, dark brown viscous liquid). MS: m / z 396.4 [M+H] + .
[0363] Weigh compound 18a (200 mg, 1.0 equiv.) into a reaction bottle, dissolve it with N,N-dimethylacetamide, then add compound 1-1 (1.2 equiv.), tripyrrolidinylphosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.), stir at room temperature, and react for 4 hours. After the reaction is completed, pour the reaction solution into water, extract it with ethyl acetate three times, combine the organic phases and concentrate them to obtain a crude product, which is purified by thin layer chromatography to obtain compound 18b (254 mg, brown solid). MS: m / z 566.0 [M+H] + .
[0364] Weigh compound 18b (200 mg, 1.0 equiv.) into a reaction bottle, dissolve it with dichloromethane, add trifluoroacetic acid (3.0 equiv.), and stir at room temperature. Monitor the progress of the reaction by TLC every 2 hours. If the reaction is not completed, add trifluoroacetic acid. After the reaction is completed, concentrate under reduced pressure, dissolve it with dichloromethane, and then concentrate under reduced pressure (repeat several times) to remove excess trifluoroacetic acid to obtain compound 18c (163 mg, yellow-brown solid). MS: m / z 466.0 [M+H] + .
[0365] Weigh compound 18c (100 mg, 1.0 equiv.) into a reaction bottle, dissolve it with dichloromethane, then add triethylamine (3.0 equiv.) and carbon disulfide (1.0 equiv.), and stir at room temperature. After the liquid quality monitoring raw materials are completely consumed, triethylamine (3.0 equiv.) and iodomethane (2.0 equiv.) are added in sequence, and the reaction is carried out at room temperature for 2 hours. After the reaction is completed, it is concentrated under reduced pressure to obtain a crude product, and liquid phase preparation is obtained to obtain compound 18 (11.6 mg). MS: m / z 556.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99 -7.53(m,5H),7.45-7.29(m,2H),6.95-6.91(m,1H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),2.95-2.79(m,1H),2.70-2.64(m,1H),2.62(s,3H),1.83-1.61(m,7H).
[0366] Example 19: Preparation of Compound 19
[0367]
[0368] Except that iodomethane was replaced by deuterated iodomethane, the other conditions were the same as those for the preparation of compound 18 to obtain compound 19, MS: m / z 559.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99 -7.53(m,5H),7.45-7.29(m,2H),6.95-6.91(m,1H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),2.95-2.79(m,1H),2.70-2.64(m,1H),1.83-1.61(m,7H).
[0369] Example 20: Preparation of Compound 20
[0370]
[0371] Except that iodomethane was replaced by S-20, the other conditions were the same as those for the preparation of compound 18 to obtain compound 20, MS: m / z 655.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99-7.53 (m, 5H), 7.45-7.29 (m,2H),6.95-6.91(m,1H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),2.95-2.79(m,5H),2.70-2.64(m,1H),2.45(s,6H),1.83-1.61(m,7H).
[0372] Example 21: Preparation of Compound 21
[0373]
[0374] Except that iodomethane was replaced by S-21, the other conditions were the same as those for the preparation of compound 18 to obtain compound 21, MS: m / z 613.2 [M+H] + .
[0375] Example 22: Preparation of Compound 22
[0376]
[0377] Except that iodomethane was replaced by S-22, the other conditions were the same as those for the preparation of compound 18 to obtain compound 22, MS: m / z 600.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99-7.53 (m, 5H), 7.45-7.29 (m,2H),6.95-6.91(m,1H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),3.28(s,3H),2.95-2.79(m,5H),2.70-2.64(m,1H),1.83-1.61(m,7H).
[0378] Example 23: Preparation of Compound 23
[0379]
[0380] Except that iodomethane was replaced by S-23, the other conditions were the same as those for the preparation of compound 18 to obtain compound 23, MS: m / z 584.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99-7.53 (m, 5H), 7.45-7.29 (m,2H),6.95-6.91(m,1H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),2.95-2.79(m,1H),2.70-2.64(m,2H),1.83-1.61(m,7H),1.38-1.34(m,6H).
[0381] Example 24: Preparation of Compound 24
[0382]
[0383] Except that iodomethane was replaced by S-24, the other conditions were the same as those for the preparation of compound 18 to obtain compound 24, MS: m / z 595.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99-7.53 (m, 5H), 7.45-7.29 (m,2H),6.95-6.91(m,1H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),3.28(s,3H),3.20-3.08(m,4H),2.95-2.79(m,1H),2.70-2.64(m,1H),1.83-1.61(m,7H).
[0384] Example 25: Preparation of Compound 25
[0385]
[0386] Except that iodomethane was replaced by S-25, the other conditions were the same as those for the preparation of compound 18 to obtain compound 25, MS: m / z 639.3 [M+H] + . 1H NMR(400MHz, DMSO-d6)δ8.80(d,J=4.9Hz,2H),8.57(s,1H),7.98(s,2H),7.86–7. 69(m,2H),7.59(s,2H),7.42(t,J=4.9Hz,1H),7.34(d,J=8.3Hz,1H),6.91(s,1H) ,5.33(d,J=6.2Hz,1H),4.85(s,2H),4.49(s,2H),4.16(s,1H),3.87–3.68(m,3H) ,2.93(d,J=21.4Hz,3H),2.75-2.68(m,4H),1.82-1.78(m,6H),1.61-1.55(m,4H).
[0387] Example 26: Preparation of Compound 26
[0388]
[0389] Except that iodomethane was replaced by S-26, the other conditions were the same as those for the preparation of compound 18 to obtain compound 26, MS: m / z 670.2 [M+H] + .
[0390] Example 27: Preparation of Compound 27
[0391]
[0392] 50 mg of compound 26 was weighed and placed in a reaction bottle, 2 mL of 4M HCl / dioxane solution was added, reacted at room temperature for 2 h, and concentrated under reduced pressure to obtain compound 27 (41 mg), MS: m / z 614.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ9.33(s,1H),8.80(d,J=4.9Hz,2H),8.65(s,1H),8.42(d,J=9.2Hz,1H),8 .18(s,1H),8.02(s,1H),7.94(d,J=8.4Hz,1H),7.79(d,J=8.7Hz,1H),7.55(s,1H),7.43(t,J=5. 0Hz,1H),7.17(d,J=9.3Hz,1H),6.34(s,1H),5.35–5.20(m,1H),4.99–4.77(m,2H),4.64–4.42(m ,4H),4.13(s,1H),3.46(t,J=7.0Hz,2H),2.68(t,J=6.9Hz,4H),1.70–1.52(m,2H),1.23(s,2H).
[0393] Example 28: Preparation of Compound 28
[0394]
[0395] Except that iodomethane was replaced by S-28, the other conditions were the same as those for the preparation of compound 18 to obtain compound 28, MS: m / z 653.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.80(d,J=4.9Hz,2H),8.57(s,1H),7.98(s,2H),7.86–7.69(m ,2H),7.59(s,2H),7.42(t,J=4.9Hz,1H),7.34(d,J=8.3Hz,1H),6.91(s,1H),5.33(d, J=6.2Hz,1H),4.85(s,2H),4.49(s,2H),4.16(s,1H),3.87–3.68(m,3H),2.93(d,J=21 .4Hz,3H),2.75-2.68(m,4H),1.82-1.78(m,6H),1.61-1.55(m,4H),1.41-1.37(m,2H).
[0396] Example 29: Preparation of Compound 29
[0397]
[0398] Except that iodomethane was replaced by S-29, the other conditions were the same as those for the preparation of compound 18 to obtain compound 29, MS: m / z 628.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.80(d,J=4.9Hz,2H),8.57(s,1H),7.98(s,2H),7.86–7.69(m,2H) ,7.59(s,2H),7.42(t,J=4.9Hz,1H),7.34(d,J=8.3Hz,1H),6.91(s,1H),5.38(s,1H),4.84 -4.73(m,2H),4.52(d,J=34.4Hz,2H),4.36(d,J=16.6Hz,1H),4.11(q,J=7.1Hz,3H),3.52( t,J=6.9Hz,2H),2.81-2.76(m,2H),2.68(s,2H),1.66–1.54(m,3H),1.26(t,J=3.1Hz,3H).
[0399] Example 30: Preparation of Compound 30
[0400]
[0401] Except that iodomethane was replaced by S-30, the other conditions were the same as those for the preparation of compound 18 to obtain compound 30, MS: m / z 598.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.78(d,J=4.9Hz,3H),8.53(s,1H),7.75(d,J=8.3Hz,2H),7. 40(t,J=4.9Hz,2H),7.31(d,J=8.2Hz,2H),6.89(s,1H),6.25(s,1H),4.85(s,1H),4.1 7(s,3H),3.70(s,3H),3.22–3.15(m,1H),3.14–3.06(m,2H),2.98(dd,J=13.6,7.9Hz, 2H), 2.62 (d, J = 6.1Hz, 1H), 2.54 (s, 3H), 2.43 (d, J = 5.6Hz, 1H), 2.00 (d, J = 6.9Hz, 2H).
[0402] Example 31: Preparation of Compound 31
[0403]
[0404] Except that iodomethane was replaced by S-31, the other conditions were the same as those for the preparation of compound 18 to obtain compound 31, MS: m / z 610.2 [M+H] + .
[0405] Example 32: Preparation of Compound 32
[0406]
[0407] Except that iodomethane was replaced by S-32, the other conditions were the same as those for the preparation of compound 18 to obtain compound 32, MS: m / z 641.2 [M+H] + .
[0408] Example 33: Preparation of Compound 33
[0409]
[0410] The same experimental method as compound 56 was used to synthesize compound 33 starting from compound 56f. MS: m / z 558.2 [M+H] + .
[0411] Example 34: Preparation of Compound 34
[0412]
[0413] Compound 18b (1.0 equiv.) was weighed and placed in a reaction bottle, and tri(2,2,6,6-tetramethyl-3,5-heptenoate)manganese (0.5 equiv.), phenylsilane (1.9 equiv.) and a dichloromethane / isopropanol mixed solvent (v / v: 1 / 10) were added in sequence. The mixture was reacted at room temperature until no raw material remained. The product 34a was obtained by filtration, concentration under reduced pressure, and column chromatography (dichloromethane / methanol = 50 / 1, v / v). MS: m / z 584.3 [M+H] + .
[0414] The same experimental method as compound 18 was used to synthesize 34 starting from compound 18b. MS: m / z 574.2 [M+H] + .
[0415] Example 35: Preparation of Compound 35
[0416]
[0417] The same experimental method as compound 56 was used to synthesize compound 35 starting from compound 56e. MS: m / z 600.2 [M+H] + .
[0418] Example 36: Preparation of Compound 36
[0419]
[0420] Except that 18b was replaced by 35a, the other conditions were the same as those for the preparation of compound 18 to obtain compound 36, MS: m / z 598.2 [M+H] + .
[0421] Example 37: Preparation of Compound 37
[0422]
[0423] Weigh compound 1-1 (0.5 g, 1.0 equiv.) and place it in a reaction bottle, then add DMF, compound 1-2 (1.2 equiv.), tripyrrolidinylphosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.) in sequence, and react at room temperature overnight. After the reaction is completed, pour the reaction solution into saturated brine, extract with ethyl acetate three times, combine the organic phases and concentrate under reduced pressure to obtain a crude product, which is separated and purified to obtain compound 37a. MS: m / z 463.1 [M+H] + .
[0424] Compound 37a (500 mg, 1.0 equiv.) was weighed into a reaction bottle, and tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (2.0 equiv.), cesium carbonate (5.0 equiv.), 2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl (0.1 equiv.) and bis(dibenzylideneacetone)palladium (0.05 equiv.) were added in sequence, tetrahydrofuran: water = 2:1 as solvent, nitrogen was replaced three times, and microwave reaction was performed at 135°C for 2 hours. After the reaction was completed, it was cooled to room temperature, filtered, concentrated, poured into water, extracted three times with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1-10: 1) to obtain a yellow oily liquid compound 37b (495 mg). MS:m / z581.4[M+H] + .
[0425] Weigh compound 37b (400 mg, 1.0 equiv.) into a reaction bottle, add dichloromethane and trifluoroacetic acid (5.0 equiv.), and stir at room temperature for 3 hours. After the reaction is completed, concentrate under reduced pressure to obtain a crude product, which is purified by silica gel column chromatography (dichloromethane: methanol = 5: 1-1: 1) to obtain a yellow-brown solid compound 37c (268 mg). MS: m / z 481.4 [M+H] + .
[0426] Weigh compound 37c (20 mg, 1.0 equiv.) into a reaction bottle, add 4 mL DMAc, add a drop of 17.5 mg / mL sodium hydroxide aqueous solution and carbon disulfide (3.0 equiv.), stir at 0°C until the raw material is consumed, then add iodomethane (3.0 equiv.), and continue to react at room temperature for 1 hour. After the reaction is completed, pour the reaction solution into water, extract three times with ethyl acetate, combine the organic phases, wash the organic phases with saturated sodium chloride aqueous solution, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain a crude product. The crude product is purified by thin layer chromatography (dichloromethane: methanol = 40: 1) to obtain a white solid compound 37 (10 mg). MS: m / z 571.2 [M+H] + .
[0427] Example 38: Preparation of Compound 38
[0428]
[0429] Except that tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate was replaced by S-38, the other conditions were the same as those for the preparation of compound 37 to obtain compound 38, MS: m / z 559.2 [M+H] + .
[0430] Example 39: Preparation of Compound 39
[0431]
[0432] Weigh NaH (188 mg, 60%, 4.7 mmol, 1.1 equiv.) into a reaction bottle, add 23 mL of DMF and cool to 0°C. Slowly drop 2-amino-1-propanol (321 mg, 1.0 equiv.) into the reaction system, warm to room temperature after the addition is complete, react for 1 h, cool to 0°C again, and slowly drop iodomethyltributyltin solution (1.84 g, 1.0 equiv., dissolved in 20 mL of DMF). After the addition is complete, warm the reaction system to room temperature and react for 3 h. After the reaction was completed, the reaction system was cooled to 0°C, saturated aqueous ammonium chloride (5 mL) was added for quenching, and EA / H2O (4 / 1, 50 mL) was added. After separation, the aqueous phase was extracted with EA (3*20 mL), and the organic phases were combined, washed with saturated brine (3*15 mL), dried over Na2SO4, filtered, concentrated under reduced pressure, and chromatographed on a silica gel column (EA / MeOH=10 / 1+0.1% Et3N) to give compound 39a (1.40 g, yellow liquid).
[0433] Add the following to the dry reaction bottle: Molecular sieves (2.00 g, 2.64 mmol), compound 39a (2.64 mmol), 5-trifluoromethyl-2-formylpyridine (2.64 mmol) and DCM (10 mL) were reacted at room temperature for 5 h until the reaction of 5-trifluoromethyl-2-formylpyridine was complete. The mixture was filtered and concentrated under reduced pressure to obtain compound 39b (no purification was required and the next step of the reaction was directly carried out).
[0434] Cu(OTf)2 (191 mg, 0.528 mmol), Rac-PhBox (176 mg, 0.528 mmol) and HFIP (4 mL) were added to a dry reaction bottle in sequence, and the nitrogen was replaced three times. After reacting at 23°C for 7 h, a solution of compound 39b (1316 mg, 2.64 mmol, dissolved in 19 mL HFIP) was added. After reacting for 16 h, 30% NH4OH and saturated brine (1 / 1, 10 mL) were added to the reaction system and stirred for 1 h. After separation, the aqueous phase was extracted with DCM, the organic phases were combined, dried with Na2SO4, and silica gel column chromatography (PE / EA=1 / 1) was performed to obtain compound 39c (620 mg). MS: m / z 246.8 [M+H] + .
[0435] Compound 39c (80 mg, 1.0 equiv.), compound 1-1 (1.2 equiv.), PyBrop (2.0 equiv.), TEA (4.0 equiv.) and DMAc (1.0 mL) were added to a dry reaction bottle in sequence. After reacting at room temperature for 20 h, a mixed solution of saturated saline / EA (4 / 1, 30 mL) was added. After separation, the aqueous phase was extracted with EA, the organic phases were combined, dried with Na2SO4, and chromatographed on a silica gel column (PE / EA=1 / 1) to obtain compound 39 (10 mg). MS: m / z 417.2 [M+H] + .
[0436] Intermediate Preparation Example 2: Synthesis of Compounds 40-1, 41-1 and 46-1
[0437] Synthesis of compound 40-1:
[0438]
[0439] Weigh compound 1-1b (200 mg, 1.0 equiv.) and place it in a reaction bottle, add dioxane: ethanol: water = 3:1:1, stir and dissolve, then add methylboric acid (2.0 equiv.), sodium carbonate (3.0 equiv.) and Pd(PPh3)4 (0.1 equiv.) in sequence, protect with nitrogen, heat to reflux at 100°C, and react for 5 hours. After the reaction is completed, filter the reaction mixture, wash the filter cake with ethyl acetate, concentrate the filtrate under reduced pressure, and purify by silica gel column chromatography (PE:EA = 15:1-5:1) to obtain compound 40-1a. MS: m / z 217.1 [M+H] + .
[0440] Weigh compound 40-1a (1.0 equiv.) and place it in a reaction bottle. Add isopropanol: water = 1:1 and sodium hydroxide (4.0 equiv.) in sequence and react at room temperature for 3 hours. After the reaction is completed, concentrate under reduced pressure, add 1M hydrochloric acid dropwise to the reaction solution until a large amount of precipitate is generated, filter, wash the filter cake with water, and dry the filter cake to obtain compound 40-1. MS: m / z 203.1 [M+H] + .
[0441] Synthesis of compound 41-1:
[0442]
[0443] Weigh compound 1-1b (1.0 equiv.) and place it in a reaction bottle, add isopropanol: water = 1:1, sodium hydroxide (4.0 equiv.) in sequence, and react at room temperature for 3 hours. After the reaction is completed, concentrate under reduced pressure, add 1M hydrochloric acid dropwise to the reaction solution until a large amount of precipitate is generated, filter, wash the filter cake with water, and dry the filter cake to obtain compound 41-1. MS: m / z 267.0 [M+H] + .
[0444] Synthesis of compound 46-1:
[0445]
[0446] Except that methylboronic acid was replaced by cyclopropylboronic acid, the other conditions were the same as those for the preparation of compound 40-1 to obtain compound 46-1, MS: m / z 229.1 [M+H] + .
[0447] Examples 40 and 41: Preparation of Compounds 40 and 41
[0448] Example 40: Preparation of Compound 40
[0449]
[0450] Except that 1-1 was replaced by 40-1, the other conditions were the same as those for the preparation of compound 39 to obtain compound 40, MS: m / z 431.2 [M+H] + .
[0451] Example 41: Preparation of Compound 41
[0452]
[0453] Except that 1-1 was replaced by 41-1, the other conditions were the same as those for the preparation of compound 39 to obtain compound 41, MS: m / z 495.1 [M+H] + .
[0454] Example 42: Preparation of Compound 42
[0455] Synthesis of compound 42-1:
[0456]
[0457] Weigh 5-trifluoromethyl-2-pyridinemethylamine hydrochloride (2g, 1.0equiv.) into a reaction bottle, add dichloromethane, stir to dissolve, add 2-acetylpyrimidine (1.15equiv.) and potassium acetate (1.30equiv.) in turn, stir at room temperature for 30 minutes, slowly add sodium triacetoxyborohydride (1.20equiv.), and continue to react at room temperature for 5 hours. After the reaction is completed, add saturated brine, separate the liquids, and extract the aqueous phase with dichloromethane three times. After TLC confirms that there is no product remaining in the aqueous phase, combine the organic phases and concentrate under reduced pressure to obtain a crude product, which is separated and purified by silica gel column chromatography (PE:EA=2:1-0:1) to obtain compound 42-1 (1.96g, yellow-brown oil). MS: m / z 283.0[M+H] + .
[0458] Synthesis of compound 42:
[0459]
[0460] Under nitrogen protection, 5-methylphthalide (5.00 g, 26.04 mmol, 1.0 equiv.), potassium tert-butoxide (292.00 mg, 2.61 mmol, 0.1 equiv.) and N,N-dimethylformamide dimethyl acetal (20 mL) were added to the reaction bottle, and the temperature was raised to 110°C for 20 hours. The system was cooled to room temperature and concentrated, and petroleum ether (100 mL) was added to slurry for 30 minutes, and filtered to obtain a solid, and ethyl acetate (100 mL) was added to slurry for 30 minutes, and filtered to obtain compound 42a (3.73 g, solid). MS: m / z 248.1 [M+H] + .
[0461] Compound 42a (3.63 g, 1.47 mmol, 1.0 equiv.), hydrazine hydrate (2.29 g, 3.68 mmol, 2.5 equiv., 80%) and ethanol (40 mL) were added to the reaction flask, heated to 70°C, and reacted for 6 hours. The system was cooled to room temperature and filtered to obtain compound 42b (3.00 g). MS: m / z 262.1 [M+H] + .
[0462] Compound 42b (1.00 g, 3.83 mmol, 1.0 equiv.), sodium hydroxide (612.80 mg, 15.32 mmol, 4.0 equiv.), isopropanol (10 mL) and water (10 mL) were added to the reaction flask and reacted at room temperature overnight. Sodium hydroxide (306.40 mmol, 7.66 mmol, 2.0 equiv.) was added and the reaction was continued at room temperature for 6 hours. The system was decompressed to remove part of the isopropanol, and ethyl acetate (50 mL) was added for extraction once. The aqueous phase was freeze-dried, and DCM:MeOH (20:1, 200 mL) was added. The mixture was stirred for 1 hour and filtered to obtain compound 42c (1.89 g, solid, crude product). MS: m / z 248.1 [M+H] + .
[0463] Compound 42c (500.00 mg, 2.02 mmol, 1.0 equiv.), compound 42-1 (682.44 mg, 2.42 mmol, 1.2 equiv.), PyBrop (1.89 g, 4.04 mmol, 2.0 eq), triethylamine (615.00 mg, 6.06 mmol, 3.0 eq) and DMAc (10 mL) were added to the reaction bottle and reacted at room temperature for 8 hours. The system was quenched by adding water (40 mL), and ethyl acetate (80 mL) was added to extract twice. The organic phases were combined and washed once with water (20 mL) and saturated sodium chloride aqueous solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin layer chromatography (DCM: MeOH = 10: 1) to obtain compound 42d. MS: m / z 512.2 [M+H] + .
[0464] Under nitrogen protection, compound 42d (200.00 mg, 0.3914 mmol, 1.0 equiv.) and tetrahydrofuran (6 mL) were added to the reaction flask, the temperature was lowered to 0°C, isobutyl chloroformate (106.91 mg, 0.7828 mmol, 2.0 equiv.) was added dropwise, the temperature was raised to room temperature, and the reaction was allowed to proceed overnight. Hydrochloric acid (1.00 mL, 0.5 M) was added to the reaction system, and the reaction was allowed to proceed at room temperature for 4 hours. Water (20 mL) was added to the system, and ethyl acetate (50 mL) was added to extract twice, the organic phases were combined, and washed once with water (20 mL) and saturated sodium chloride aqueous solution (20 mL), the organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin layer chromatography (dichloromethane: methanol = 15:1) to obtain compound 42e (69.00 mg). MS: m / z 503.1 [M+H] + .
[0465] Compound 42e (69.00 mg, 0.1375 mmol, 1.0 equiv.), phthalimide (30.35 mg, 0.2063 mmol, 1.5 equiv.), potassium carbonate (37.95 mg, 0.2750 mmol, 2.0 equiv.) and DMF (5 mL) were added to the reaction flask and reacted at room temperature for 6 hours. Water (20 mL) was added to the system to quench the reaction, and ethyl acetate (50 mL) was added to extract twice. The organic phases were combined and washed once with water (20 mL) and saturated sodium chloride aqueous solution (20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 42f (150.00 mg, crude product). MS: m / z 614.2 [M+H] + .
[0466] Compound 42f (150 mg, crude product), hydrazine hydrate (37.35 mg, 0.7460 mmol, 3.1 equiv., 80%) and ethanol (4 mL) were added to the reaction flask, and the temperature was raised to 70°C for 4 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by reverse phase silica gel column chromatography (Shim-pack GIS C18 20*250 mm, 5 μm; 0.01% formic acid-water / acetonitrile) to obtain compound 42 (15 mg). MS: m / z 484.2 [M+H] + .
[0467] Example 43: Preparation of Compound 43
[0468]
[0469] Add the following to the dry reaction bottle: Molecular sieves (2.00 g, 2.64 mmol), compound 39a (2.64 mmol), 5-bromo-2-formylpyridine (2.64 mmol) and DCM (10 mL) were reacted at room temperature for 5 h until the reaction of 5-bromo-2-formylpyridine was complete. The mixture was filtered and concentrated under reduced pressure to obtain compound 43a (no purification was required and the next step was directly carried out).
[0470] Cu(OTf)2 (191 mg, 0.528 mmol), Rac-PhBox (176 mg, 0.528 mmol) and HFIP (4 mL) were added to a dry reaction bottle in sequence, and the nitrogen was replaced three times. After reacting at 23°C for 7 h, a solution of compound 43a (1316 mg, 2.64 mmol, dissolved in 19 mL HFIP) was added. After reacting for 16 h, 30% NH4OH and saturated brine (1 / 1, 10 mL) were added to the reaction system and stirred for 1 h. After separation, the aqueous phase was extracted with DCM, the organic phases were combined, dried with Na2SO4, and silica gel column chromatography (PE / EA=1 / 1) was performed to obtain compound 43b. MS: m / z 257.0 [M+H] + .
[0471] Weigh compound 43b (200 mg, 1.0 equiv.) and place it in a reaction bottle, add dioxane: ethanol: water = 3: 1: 1, stir and dissolve, then add N-Boc-tetrahydropyridine-4-boronic acid pinacol ester (1.2 equiv.), tripotassium phosphate (3.0 equiv.) and Pd(dppf)Cl2 (0.1 equiv.) in sequence, protect with nitrogen, heat under reflux at 100°C, and react for 5 hours. After the reaction is completed, filter the reaction mixture, wash the filter cake with ethyl acetate, concentrate the filtrate under reduced pressure, and purify by silica gel column chromatography (dichloromethane: methanol = 15: 1-10: 1) to obtain compound 43c (245 mg, dark brown viscous liquid). MS: m / z 360.2 [M+H] + .
[0472] Weigh compound 43c (200 mg, 1.0 equiv.) into a reaction bottle, dissolve it with N,N-dimethylacetamide, then add compound 41-1 (1.2 equiv.), tripyrrolidinylphosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.), stir at room temperature, and react for 4 hours. After the reaction is completed, pour the reaction solution into water, extract it with ethyl acetate three times, combine the organic phases and concentrate them to obtain a crude product, which is purified by thin layer chromatography to obtain compound 43d. MS: m / z 608.2 [M+H] + .
[0473] Weigh compound 43d (200 mg, 1.0 equiv.) into a reaction bottle, dissolve it with dichloromethane, add trifluoroacetic acid (3.0 equiv.), and stir at room temperature. Monitor the progress of the reaction by TLC every 2 hours. If the reaction is not completed, add trifluoroacetic acid. After the reaction is completed, concentrate under reduced pressure, dissolve it with dichloromethane, and then concentrate under reduced pressure (repeat several times) to remove excess trifluoroacetic acid to obtain compound 43e. MS: m / z 508.1 [M+H] + .
[0474] Weigh compound 43e (100 mg, 1.0 equiv.) into a reaction bottle, dissolve it with dichloromethane, then add triethylamine (3.0 equiv.) and carbon disulfide (1.0 equiv.), and stir at room temperature. After the liquid quality monitoring raw materials are completely consumed, triethylamine (3.0 equiv.) and iodomethane (2.0 equiv.) are added in sequence, and react at room temperature for 2 hours. After the reaction is completed, concentrate under reduced pressure to obtain a crude product, which is purified by thin layer chromatography to obtain compound 43. MS: m / z 598.1 [M+H] + .
[0475] Intermediate Preparation Example 3: Synthesis of Compounds 47-1, 48-1, 52-1 to 55-1:
[0476] Synthesis of compound 47-1:
[0477]
[0478] 4-Oxotetrahydrofuran-3-carbonitrile (0.5 g) was weighed and placed in a round-bottom flask, and dichloromethane (5.0 mL) and DIPEA (1.2 equiv.) were added in sequence, and the reaction system was cooled to -78°C. Trifluoroacetic anhydride (1.0 equiv.) was then added dropwise to the reaction system and stirred for 15 minutes. After the reaction was completed, water was added to the reaction system, and the organic phase was separated. The organic phase was washed with saturated brine (10 mL × 2), dried over anhydrous sodium sulfate, and concentrated under pressure to obtain compound 47-1-P1, which was directly used in the next step without purification.
[0479] Weigh 4-amino-3-bromobenzoic acid methyl ester (1.0 equiv.), 1,4-dioxane (20 mL), bis(pinacolato)diboron (1.5 equiv.), potassium acetate (2.0 equiv.) and Pd(dppf)Cl2 (0.1 equiv.) in turn and add them into a round-bottom flask, replace nitrogen three times, and heat under reflux at 85°C for 6 hours. After the reaction is completed, cool to room temperature and concentrate under reduced pressure to obtain a crude product. The crude product is purified by silica gel column chromatography (PE:EA=5:1-3:1) to obtain a yellow solid compound 47-1a. MS: m / z 278.1[M+H] + .
[0480] Compound 47-1a (1.0 equiv.), compound 47-1-P1 (1.5 equiv.), potassium carbonate (3.0 equiv.), Pd(PPh3)4 (0.1 equiv.), 1,4-dioxane / water (10 / 1) were weighed in turn and added to a round-bottom flask, nitrogen was replaced three times, and the mixture was heated and refluxed at 85°C until compound 47-1a was completely consumed. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography to obtain compound 47-1b. MS: m / z 245.1 [M+H] + .
[0481] Weigh compound 47-1b (1.0 equiv.) and place it in a reaction bottle. Add isopropanol: water = 1:1 and sodium hydroxide (4.0 equiv.) in sequence and react at room temperature for 3 hours. After the reaction is completed, concentrate under reduced pressure, add 1M hydrochloric acid dropwise to the reaction solution until a large amount of precipitate is generated, filter, wash the filter cake with water, and dry the filter cake to obtain compound 47-1. MS: m / z 231.1 [M+H] + .
[0482] Synthesis of compound 48-1:
[0483]
[0484] Except that 4-oxotetrahydrofuran-3-carbonitrile was replaced by S-48, the other conditions were the same as those for the preparation of compound 47-1 to obtain compound 48-1, MS: m / z 229.1 [M+H] + .
[0485] Synthesis of compound 52-1:
[0486]
[0487] Except that 4-amino-3-bromobenzoic acid methyl ester was replaced by S-52, the other conditions were the same as those for the preparation of compound 47-1 to obtain compound 52-1, MS: m / z 265.0 [M+H] + .
[0488] Synthesis of compound 53-1:
[0489]
[0490] Except that 4-amino-3-bromobenzoic acid methyl ester was replaced by S-53 and 47-1-P1 was replaced by 53-1-P1, the other conditions were the same as those for the preparation of compound 47-1 to obtain compound 53-1, MS: m / z 261.1 [M+H] + .
[0491] Synthesis of compound 54-1:
[0492]
[0493] Except that S-53 was replaced by S-54, the other conditions were the same as those for the preparation of compound 53-1 to obtain compound 54-1, MS: m / z 244.1 [M+H] + .
[0494] Synthesis of compound 55-1:
[0495]
[0496] Except that 47-1-P1 was replaced by 53-1-P1, the other conditions were the same as those for the preparation of compound 47-1 to obtain compound 55-1, MS: m / z 243.1 [M+H] + .
[0497] Example 44: Preparation of Compound 44
[0498]
[0499] Except that 1-2 was replaced by 43b, the other conditions were the same as those for the preparation of compound 37a to obtain compound 44a, MS: m / z 427.1 [M+H] + .
[0500] Except that 37a was replaced by 44a, the other conditions were the same as those for the preparation of compound 38 to obtain compound 44, MS: m / z 601.1 [M+H] + .
[0501] Example 45: Preparation of Compound 45
[0502]
[0503] Except that 41-1 was replaced by 40-1, the other conditions were the same as those for the preparation of compound 43 to obtain compound 45, MS: m / z 534.2 [M+H] + .
[0504] Example 46: Preparation of Compound 46
[0505]
[0506] Except that 41-1 was replaced by 46-1, the other conditions were the same as those for the preparation of compound 43 to obtain compound 46, MS: m / z 560.2 [M+H] + .
[0507] Example 47: Preparation of Compound 47
[0508]
[0509] Except that 41-1 was replaced by 47-1, the other conditions were the same as those for the preparation of compound 43 to obtain compound 47, MS: m / z 562.2 [M+H] + .
[0510] Example 48: Preparation of Compound 48
[0511]
[0512] Except that 41-1 was replaced by 48-1, the other conditions were the same as those for the preparation of compound 43 to obtain compound 48, MS: m / z 560.2 [M+H] + .
[0513] Example 49: Preparation of Compound 49
[0514]
[0515] Except that 1-1 was replaced by 40-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 49, MS: m / z 570.2 [M+H] + .
[0516] Example 50: Preparation of Compound 50
[0517]
[0518] Except that 1-1 was replaced by 50-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 50, MS: m / z 590.1 [M+H] + .
[0519] Example 51: Preparation of Compound 51
[0520]
[0521] Except that 1-1 was replaced by 51-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 51, MS: m / z 604.2 [M+H] + .
[0522] Example 52: Preparation of Compound 52
[0523]
[0524] Except that 1-1 was replaced by 52-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 52, MS: m / z 632.2 [M+H] + .
[0525] Example 53: Preparation of Compound 53
[0526]
[0527] Except that 1-1 was replaced by 53-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 53, MS: m / z 628.2 [M+H] + .
[0528] Example 54: Preparation of Compound 54
[0529]
[0530] Except that 1-1 was replaced by 54-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 54, MS: m / z 611.2 [M+H] + .
[0531] Example 55: Preparation of Compound 55
[0532]
[0533] Except that 1-1 was replaced by 55-1, the other conditions were the same as those for the preparation of compound 18 to obtain compound 55, MS: m / z 610.2 [M+H] + .
[0534] Example 56: Preparation of Compound 56
[0535]
[0536] Compound 2-acetylpyrimidine (3 g, 24.56 mmol, 1.0 equiv.), R-tert-butylsulfenamide (11.9 g, 98.26 mmol, 4.0 equiv.), tetraethyl titanate (19.6 g, 85.96 mmol, 3.5 equiv.), and THF (60 mL) were added to the reaction flask, and the reaction was carried out at 80° C. for 3 h under nitrogen protection. After the reaction was completed, the reaction system was poured into ice water (200 mL), and the solid was precipitated. The solid was filtered, and the filter cake was washed with EA. The filtrate was extracted and separated. The aqueous phase was extracted with EA (100 mL) three times, and the EA phases were combined and washed once with sodium chloride aqueous solution (200 mL). The EA phase was dried over anhydrous sodium sulfate and spin-dried. The crude product was purified by silica gel column chromatography (PE:EA=2:1) to obtain compound 56a (5.5 g). MS: m / z 226.1 [M+H] + .
[0537] Compound 56a (2 g, 8.88 mmol, 1.0 equiv.) and THF / water (20 mL / 2 mL) were added to the reaction flask, cooled to -78°C, sodium borohydride (604 mg, 15.968 mmol, 1.8 equiv.) was added in batches, and the temperature was kept at -78°C for 2 h. After the reaction was completed, the reaction system was quenched with aqueous ammonium chloride solution (100 mL), extracted with EA (50 mL) six times, the EA phases were combined, washed once with aqueous sodium chloride solution (200 mL), the EA phases were dried over anhydrous sodium sulfate and spin-dried, and the crude product was purified by column chromatography (DCM: MeOH = 40: 1) to obtain compound 56b (1 g). MS: m / z 228.1 [M+H] + .
[0538] Compound 56b (1 g, 4.40 mmol, 1.0 equiv.) and 4 M hydrochloric acid dioxane solution (10 mL) were added to the reaction bottle and reacted at room temperature for 1 h. After the reaction was completed, the reaction system was spin-dried, EA (5 mL) was added to the crude product for pulping, and the solid was collected by filtration to obtain compound 56c (500 mg). MS: m / z 124.1 [M+H] + .
[0539] 56d was synthesized by the same experimental method as compound 1-2, MS: m / z 292.8 [M+H] + ; Synthesize 56e by the same experimental method as compound 18a, MS: m / z 396.4 [M+H] + .
[0540] Weigh compound 56e (200 mg, 1.0 equiv.) into a reaction bottle, dissolve it with N,N-dimethylacetamide, then add compound 40-1 (1.2 equiv.), tripyrrolidinylphosphonium bromide hexafluorophosphate (1.5 equiv.) and triethylamine (3.0 equiv.), stir at room temperature, and react for 4 hours. After the reaction is completed, pour the reaction solution into water, extract it with ethyl acetate three times, combine the organic phases and concentrate them to obtain a crude product, which is purified by thin layer chromatography to obtain compound 56f (218 mg, brown solid). MS: m / z 580.3 [M+H] + .
[0541] Weigh compound 56f (200 mg, 1.0 equiv.) into a reaction bottle, dissolve it in methanol, add Pd / C (30% wt.), and heat to 50°C for 3 h. After the reaction is complete, concentrate under reduced pressure and purify by thin layer chromatography to obtain compound 56g (121 mg, yellow-brown solid). MS: m / z 582.2 [M+H] + .
[0542] Weigh compound 56g (60 mg, 1.0 equiv.) into a reaction bottle, add dichloromethane and trifluoroacetic acid (5.0 equiv.), and stir at room temperature for 3 hours. After the reaction is completed, concentrate under reduced pressure to obtain a crude product, which is purified by silica gel column chromatography (dichloromethane: methanol = 5: 1-1: 1) to obtain a yellow-brown solid compound 56h (45 mg). MS: m / z 482.4 [M+H] + .
[0543] Weigh compound 56h (45 mg, 1.0 equiv.) into a reaction flask, dissolve it with dichloromethane, then add triethylamine (3.0 equiv.) and carbon disulfide (1.0 equiv.), and stir at room temperature. After the liquid quality monitoring raw materials are completely consumed, triethylamine (3.0 equiv.) and iodomethane (2.0 equiv.) are added in sequence, and the reaction is carried out at room temperature for 2 hours. After the reaction is completed, the crude product is concentrated under reduced pressure, and the liquid phase is prepared to obtain compound 56 (9.5 mg). MS: m / z 570.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.74 (s, 2H), 8.31 (d, J = 1.9Hz, 1H), 7.99 -7.53(m,5H),7.45-7.29(m,2H),5.93-5.34(m,1H),5.11-4.92(m,1H),4.13-4.00(m,2H),3.65 -3.54(m,2H),2.95-2.79(m,1H),2.70-2.64(m,1H),2.62(s,3H),2.32(s,3H),1.83-1.61(m,7H).
[0544] Experimental Example 1: PRMT5 enzyme inhibition activity test
[0545] 1.1 Experimental Materials
[0546] 1.1.1 Reagents and consumables
[0547]
[0548]
[0549] 1.2 Experimental process
[0550] Step 1: Preparation of 1x PRMT5 assay buffer: Add 30 μL of 500 mM DTT to 4x PRMT5 assay buffer, and prepare 1x PRMT5 assay buffer (add 3 volumes of distilled water to 4x PRMT5 assay buffer);
[0551] Step 2: Preparation of working solution of the test compound: Take 45 μL DMSO and add 5 μL 5 mM stock solution of the test compound to prepare a working solution with a concentration of 500 μM; use 500 μM working solution as the initial working solution concentration, dilute it 3 times with DMSO, and obtain another 7 working solutions of different concentrations in turn.
[0552] Step 3: Preparation of test compounds containing MTA: For each test compound, add 28 μL 1x PRMT5 assay buffer, 1 μL test compound working solution and 1 μL MTA at a concentration of 200 μM.
[0553] Step 4: Preparation of 1x PRMT5 assay buffer containing MTA: Add 29 μL 1x PRMT5 assay buffer and 1 μL 200uM MTA to each test compound.
[0554] Step 5: Mixture preparation: Take 2.0 μL 4x PRMT5 assay buffer, 0.5 μL 60 μM S-adenosylmethionine, 1 μL biotin-labeled substrate and 1.5 μL water, then add 5 μL of the above mixture to the positive control well (without the test compound), the test well (with the test compound) and the blank well (without PRMT5 enzyme and test compound) in the 96-well plate;
[0555] Step 6: Take 3 μL of the test compound containing MTA and add it to the test well; take another 3 μL of MTA 1x PRMT5 assay buffer and add it to the positive control well and blank well;
[0556] Step 7: Preparation of PRMT5 enzyme dilution solution: take out PRMT5 enzyme from -80℃ refrigerator and thaw on ice, dilute the concentration of PRMT5 enzyme to 100 ng / μL with 1x PRMT5 analysis buffer, and then take 2μL of PRMT5 enzyme dilution solution and add it to the positive control group and the test group; the final concentrations of the test compounds in the test group are 5μM, 1.667μM, 0.556μM, 0.185μM, 0.0617μM, 0.0206μM, 0.0069μM and 0.0023μM.
[0557] The specific ratio is as follows:
[0558] / Positive control group Test Group Blank group 4x PRMT5 Assay Buffer 2μL 2μL 2μL 60 μM S-adenosylmethionine 0.5μL 0.5μL 0.5μL Biotinylated substrate 1μL 1μL 1μL water 1.5μL 1.5μL 1.5μL Compounds containing MTA - 3μL - 1x PRMT5 Assay Buffer with MTA 3μL - 3μL PRMT5 enzyme (100 ng / μL) 2μL 2μL - 1x PRMT5 Assay Buffer - - 2μL total 10μL 10μL 10μL
[0559] Step 8: Preparation of 1x Assay Buffer: Take 550 μL of 4x Assay Buffer (PRMT5 Homogeneous Assay Kit) and add 1650 μL of water to obtain 1x Assay Buffer;
[0560] Step 9: Preparation of anti-rabbit IgG receptor microbead working solution: Take 498 μL 1x detection buffer, add 2 μL anti-rabbit IgG receptor microbeads, and mix well;
[0561] Step 10: Preparation of primary antibody 4-3 working solution: Take 522 μL 1x detection buffer, add 18 μL primary antibody 4-3 (PRMT5 homogeneous analysis kit), and mix well;
[0562] Step 11: Take 5 μL of each solution from step 9 and step 10, vortex mix, add to the wells to be tested in the above 96-well plate, and incubate at room temperature for 30 minutes;
[0563] Step 12: Preparation of the working solution of streptavidin-conjugated donor microbeads: Take 1054 μL of 1x detection buffer, add 8.5 μL of streptavidin-conjugated donor microbeads, mix well, take 10 μL and add it to the wells to be tested in the above 96-well plate, and incubate at room temperature for 30 minutes;
[0564] Step 13: Read the readings.
[0565] 1.3 Data Analysis
[0566] 1.3.1 Activity calculation formula
[0567] %Inhibition=(Signal postive -Signal cmpd ) / (Signal postive -Signal PC )×100.
[0568] Among them: Signal cmpd Indicates the mean signal of the test compound wells; Signal PC Indicates the average signal of blank wells; Signal postive Represents the average signal of positive control wells.
[0569] 1.3.2 Calculation of compound IC using GraphPad nonlinear fitting formula 50
[0570] The log value of compound concentration was used as the X-axis and the percentage inhibition rate was used as the Y-axis. The "log (inhibitor) vs. response-variable slope" function module of the analysis software GraphPad was used to fit the dose-effect curve to obtain the inhibitory activity of each compound on PRMT5.
[0571] The fitting formula is: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)*HillSlope))
[0572] Among them: Top represents the percentage inhibition rate at the top platform, and the Top standard of the curve is generally between 80% and 120%; Bottom represents the percentage inhibition rate at the bottom platform, and the Bottom of the curve is generally between -20% and 20%, and HillSlope represents the slope of the percentage inhibition rate curve.
[0573] Table 11. In vitro activity test results (IC 50 express)
[0574] Compound <![CDATA[IC 50 ]]> Compound <![CDATA[IC 50 ]]> 18 16.7nM 27 74.8nM 19 17.2nM 28 50.6nM 21 14.6nM 29 50.0nM 22 19.9nM 30 28.9nM 23 34.6nM 38 37.1nM 24 37.6nM 41 89.9nM 25 50.4nM 56 10.8nM
[0575] It can be seen from the above experimental results that the compounds of the present application have excellent in vitro inhibitory activity against PRMT5, so that they can be used as small molecule PRMT5 inhibitors, which have good anti-tumor effects and can be used to treat diseases such as cancer.
[0576] Although the present application has been described by way of specific examples above, it should not be construed as being limited thereto, but rather the present application encompasses the general aspects previously disclosed and may be modified and have various embodiments without departing from the spirit and scope of the present application.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, in: represents a single bond or a double bond; Every R 1 Each independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is optionally substituted with one or more halogen, cyano, hydroxyl, amino, nitro, C 1-6 Haloalkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl substituted; Every R 2 Each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is optionally substituted with one or more halogen, cyano, hydroxyl, amino, nitro, C 1-6 Haloalkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl substituted; Every R 3 are each independently selected from H, halogen, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 3-10 Cycloalkyl and 3-10 membered heterocyclic group; Or, R 1 and R 3 Connected to each other to form a 5-10 membered heterocyclic group; A is selected from 3-10 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl; R 4 Selected from H, halogen, cyano, hydroxyl, nitro, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR 1 R 2 、-C(=O)R 1 、-NHC(=O)R 1 、-SO2R 1 、-SOR 1 , C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, oxazabicyclo[3.2.1]octanyl, -C(=S)SR 6 and-P(=O)R 11 R 12 ; said C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR 1 R 2 、-C(=O)R 1 、-NHC(=O)R 1 、-SO2R 1 、-SOR 1 , C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, oxazabicyclo[3.2.1]octanyl, -C(=S)SR 6 or -P(=O)R 11 R 12 Optionally substituted with one or more substituents selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, halogen, hydroxyl, amino, cyano, nitro, =NH, =NR 3 、-C(=S)SR 6 、-(C 1-6 Alkylene)-OH, -(C 1-6 Alkylene)-NH2, C 1-6 Haloalkyl and -P(=O)R 11 R 12 ; R 5 Selected from H, -P(=O)R 11 R 12 , -R a -P(=O)R 11 R 12 , -R a -C(=S)SR 6 and-C(=S)SR 6 ;and, R 4 and R 5 Not at the same time hydrogen; Every R 11 and R 12 Each independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, NH(R c )-(C 1-6 Alkylene)- and N(R c )(C 1-6 Alkyl)-(C 1-6 Alkylene)-, or, R 11 and R 12 are connected to each other to form a 5-10 membered heterocyclic group; 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, 5-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl is optionally substituted by one or more R c replace; Every R c are each independently selected from H, halogen, O=, HN=, C 1-6 Alkoxy, (C 1-6 Alkyl)-N=, C 1-6 Alkyl, (C 1-6 alkyl)-C(=O)-, (C 1-6 Alkyl)-SO2-, (C 3-6 Cycloalkyl)-SO2-, (C 1-6 alkyl)-OC(=O)-, (C 1-6 alkyl)-O-(C 1-6 Alkylene)-, (C 1-6 alkyl)-O-(C 1-6 Alkylene)-C(=O)-, NH2-C(=O)-, (C 1-6 alkyl)-NH-C(=O)-, (C 1-6 Alkyl)2N-C(=O)-, NH2-(C 1-6 Alkylene)-C(=O)-, (C 1-6 alkyl)-NH-(C 1-6 Alkylene)-C(=O)-, (C 1-6 Alkyl)2N-(C 1-6 Alkylene)-C(=O)-, NH2-C(=O)-(C 1-6 Alkylene)-, (C 1-6 alkyl)-NH-C(=O)-(C 1-6 Alkylene)-, (C 1-6 alkyl)2N-C(=O)-(C 1-6 Alkylene)-, C 3-6 Cycloalkyl, (C 3-6 Cycloalkyl)-C(=O)-, (C 3-6 Cycloalkyl)-(C 1-6 alkylene)-, 3-10 membered heterocyclic group, (3-10 membered heterocyclic group)-C(=O)-, (3-10 membered heterocyclic group)-(C 1-6 Alkylene)-, (C 6-10 Aryl)-(C 1-6 Alkylene)- and C substituted by one or more hydroxyl or cyano groups 1-6 Alkyl; when R c When it is not H, halogen or O=, R c optionally substituted with one or more halogens; R a Selected from C 1-6 Alkylene, -(C 3-8 cycloalkyl)-(C=O)-, 3-10 membered heterocyclyl, 5-10 membered heteroaryl and C 6-10 Aryl; the 3-10 membered heterocyclic group, 5-10 membered heteroaryl or C 6-10 The aryl group is optionally substituted with one or more halogen, cyano, hydroxy, nitro, amino, aldehyde, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Haloalkoxy substitution; Every R 6 Each independently selected from H, C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-(3-8 membered heterocyclic group), C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -(C 1-6 Alkylene)-OH, -(C 1-6 Alkylene)-NH2, -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-NH-(C 1-6 Alkyl), -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)NH(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)N(C 1-6 Alkyl)2, -SOR 1 and-SO2R 1 ; X1 for CR 3 or N; X2 for CR 3 or N; X3 for CR 3 , C(R 3 )2. NR 3 , C=O or N; X4 for CR 10 or N; X5 for CR 9 or N; R 7 is H or methyl; R 8 Selected from H, halogen, alkynyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy and -(C 1-6 Alkylene)-NH2; If present, R 9 Selected from H, halogen, alkynyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy and C 3-10 Cycloalkyl; Or, if present, R 8 and R 9 Connect to each other to form C 3-10 Cycloalkenyl, 5-10 membered heterocyclyl or 5-10 membered heteroaryl; the 5-10 membered heterocyclyl or 5-10 membered heteroaryl each independently contains at least one N, O or S; If present, R 10 is selected from H, amino, hydroxyl and carboxyl; m is 0, 1, 2, 3 or 4; Furthermore, the compound having the structure of Formula I satisfies the following conditions at the same time: Condition 1: When R 5 is H, and R 1 and R 3 When they are not connected to each other to form a 5-10 membered heterocyclic group, X3 is not N; Condition 2: When R 8 and R 9 When connected to form a 5-10 membered heterocyclic group, R 4 For H.
2. The compound according to claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, wherein: R 1 is a 5-10 membered heteroaryl group, preferably a 5-10 membered N-containing heteroaryl group, more preferably a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, an indolyl group or a quinolyl group, and further preferably a pyrimidinyl group; R 2 C 1-6 Alkyl, preferably methyl, ethyl or propyl, more preferably methyl; R 3 is H; Or, R 1 and R 3 are connected to each other to form a 5-10 membered heterocyclic group; preferably, the 5-10 membered heterocyclic group is a 5-10 membered heterocycloalkyl group, preferably a morpholinyl group, a thiomorpholinyl group, a 1,3-oxazinyl group, a 1,4-nitrogen phosphorus hexacyclyl group, a piperazinyl group or a piperidinyl group, more preferably a morpholinyl group or a thiomorpholinyl group; A is a 5- to 14-membered heteroaryl group, preferably a 5- to 14-membered N-containing heteroaryl group, more preferably a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, an indolyl group or a quinolyl group, and further preferably a pyridyl group.
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, wherein: R 4 H or C 1-6 Haloalkyl; R 5 H, -P(=O)R 11 R 12 or -R a -C(=S)SR 6 ;and R 4 and R 5 Not at the same time H; R 11 and R 12 Each independently is C 1-6 Alkyl (preferably methyl, ethyl, propyl or isopropyl), C 2-6 Alkenyl (preferably vinyl or allyl), C 3-10 Cycloalkyl (preferably cyclopropyl), C 6-10 Aryl (preferably phenyl or naphthyl) or 5-10 membered heteroaryl (preferably thiazolyl), or R 11 and R 12 Connected to form a 5-10 membered heterocyclic group (preferably ); said C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 5-10 membered heterocyclic group is optionally substituted by one or more R c replace; R c For halogen, C 1-6 Alkyl, C 1-6 Alkoxy or (C 3-10 cycloalkyl)-C(=O)-, preferably fluorine, chlorine, methyl, ethyl, propyl, methoxy, cyclopropane-C(=O)-, cyclobutane-C(=O)-, cyclopentane-C(=O)- or cyclohexane-C(=O)-, more preferably fluorine, chlorine, methyl, methoxy or cyclopropane-C(=O)-; R a is a 3-10 membered heterocyclyl (preferably a 3-10 membered heterocycloalkyl, a 3-10 membered heterocycloalkenyl or a 3-10 membered heterospirocyclyl); the 3-10 membered heterocycloalkyl, the 3-10 membered heterocycloalkenyl or the 3-10 membered heterospirocyclyl is optionally substituted by one or more hydroxyl groups; further, the 3-10 membered heterocycloalkyl is a piperidinyl, a piperazinyl or an azacycloheptyl; the 3-10 membered heterocycloalkenyl is The 3-10 membered heterospirocyclic group is 2,6-diazaspiro[3.3]heptyl; R 6 C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 Alkylene)-(3-8 membered heterocyclic group), C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(=O)O(C 1-6 alkyl) or -(C 1-6 Alkylene)-C(=O)N(C 1-6 Preferably, the 3-10 membered heterocyclic group or the -(C 1-6 The 3-8 membered heterocyclic group in the alkylene)-(3-8 membered heterocyclic group) is a 3-8 membered O- or N-containing heterocyclic group, preferably a 4-6 membered O- or N-containing heterocyclic group, more preferably an oxetanyl, tetrahydropyrrolyl, morpholinyl or piperidinyl group; m is 0.
4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, wherein: X1 for CR 3 or N, where R 3 is H or halogen, preferably H; X2 for CR 3 , where R 3 is H; X3 is C=O or N, preferably N; X4 for CR 10 or N, where R 10 is H or amino, preferably amino; X5 for CR 9 or N, where R 9 H, halogen, C 1-6 Alkyl or C 3-10 Cycloalkyl, preferably H or halogen; R 7 is H; R 8 H or -(C 1-6 Alkylene) -NH2, preferably H; Or, R 8 and R 9 Connect to each other to form C 3-10 cycloalkenyl, 5-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl or 5-10 membered heteroaryl each independently contains at least one O, N or S; preferably, the C 3-10 Cycloalkenyl is The 5-10 membered heterocyclic group is The 5-10 membered heteroaryl group is 5. The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, wherein: The structure of the compound is shown in Formula I-1 or Formula I-2: Among them: X1, X3~X5, R1~R5, R7~R8 and As defined in any one of claims 1 to 4; Alternatively, the structure of the compound is as shown in Formula I-3A: Among them: X1, R1~R5 and R7~R 10 As defined in any one of claims 1 to 4; Alternatively, the structure of the compound is as shown in Formula I-3B: Among them: R1~R5, R7, R8 and R 10 As defined in any one of claims 1 to 4; Alternatively, the structure of the compound is as shown in Formula I-4A1: Wherein: X1, R3-R5 and R7-R9 are as defined in any one of claims 1-4; or, the structure of the compound is as shown in Formula I-4A2: Wherein: X1, R3-R5 and R7 are as defined in any one of claims 1-4; or, the structure of the compound is as shown in Formula I-4A3: Wherein: X1, R3-R5 and R7 are as defined in any one of claims 1-4; or, the structure of the compound is as shown in Formula I-4A4: Wherein: R4-R5 and R7-R9 are as defined in any one of claims 1-4; or, the structure of the compound is as shown in Formula I-4A5: Wherein: R4-R5 and R7 are as defined in any one of claims 1-4; Alternatively, the structure of the compound is as shown in Formula I-4A6: Wherein: R4-R5 and R7 are as defined in any one of claims 1-4; Alternatively, the structure of the compound is as shown in Formula I-4B: Wherein: R3-R5 and R7-R8 are as defined in any one of claims 1-4.
6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, wherein: represents a double bond; R 1 Each independently is C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms; R 2 Each independently is C 1-6 alkyl; R 3 Each independently is H; Or, R 1 and R 3 are connected to each other to form a 5-10 membered heterocycloalkyl group containing 1-3 N, O or S atoms; A is C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms; R 4 H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-10 Cycloalkyl, or a 3-10 membered heterocyclic group containing 1-3 N, O or S atoms, wherein the C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl are optionally substituted by one or more substituents selected from halogen and -C(=S)SR 6 ; R 5 H, or -R a -C(=S)SR 6 ; and, R 4 and R 5 Not at the same time H; R a is a 3-10 membered heterocyclic group containing 1-3 N, O or S atoms; R 6 Each independently selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 alkylene)-(3-8 membered heterocyclic group), 3-10 membered heterocyclic group, -(C 1-6 Alkylene)-NH-(C 1-6 Alkyl), -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), the heterocyclic group contains 1-3 N, O or S atoms; X1 is CH; X2 is CH; X3 is N; X4 for CR 10 ; X5 for CR 9 ; R 7 is H; R 8 is H; R 9 is H or halogen; R 10 is H or amino; Preferably, represents a double bond; R 1 is pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; R 2 C 1-6 alkyl; R 3 is H; Or, R 1 and R 3 Connected to each other to form morpholinyl, thiomorpholinyl, 1,3-oxazinyl, 1,4-nitrogen phosphorus hexacyclyl, piperazinyl or piperidinyl; A is pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; R 4 For H, R 5 For-R a -C(=S)SR 6 ; or R 4 C 1-6 Haloalkyl, R 5 is H; R a For piperidinyl, piperazinyl, R 6 Each independently selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl, -(C 1-6 alkylene)-(5-6 membered heterocyclic group), 4-5 membered heterocyclic group, -(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-O-(C 1-6 Alkyl), -(C 1-6 Alkylene)-CN, -(C 1-6 Alkylene)-C(=O)OH, -(C 1-6 Alkylene)-C(=O)O(C 1-6 Alkyl), the heterocyclic group contains 1-2 N or O atoms; X1 is CH; X2 is CH; X3 is N; X4 for CR 10 ; X5 for CR 9 ; R 7 is H; R 8 is H; R 9 is H or halogen; R 10 It is amino.
7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, wherein the compound is selected from:
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof; Preferably, the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier; More preferably, the pharmaceutically acceptable carrier includes one or more of a diluent, a binder, a disintegrant, a lubricant, a wetting agent, a thickener, a glidant, a flavoring agent, an olfactory agent, a preservative, an antioxidant, a pH adjuster, a solvent, a cosolvent, a surfactant and an opacifier.
9. A pharmaceutical preparation, which is prepared from the compound according to any one of claims 1 to 7 or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug, or the pharmaceutical composition according to claim 8; Preferably, the pharmaceutical preparation is a solid preparation for oral administration, preferably a capsule, tablet, pill, powder or granule; or Preferably, the pharmaceutical preparation is a liquid dosage form for oral administration, preferably an emulsion, solution, suspension, syrup or tincture; or Preferably, the pharmaceutical preparation is a dosage form for parenteral injection, preferably a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion; or Preferably, the pharmaceutical preparation is in the form of a topical administration, preferably an ointment, powder, suppository, drops, spray or inhalant.
10. Use of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope-labeled substance or prodrug thereof, or a pharmaceutical composition according to claim 8, or a pharmaceutical preparation according to claim 9 in the preparation of a medicament for preventing and / or treating a disease mediated at least in part by PRMT5; Preferably, the disease at least partially mediated by PRMT5 is cancer, cardiovascular disease or myelofibrosis; More preferably, the cancer includes glioblastoma, melanoma, blood tumor (preferably leukemia, lymphoma or multiple myeloma), bladder urothelial carcinoma, colorectal cancer, lung cancer, gastric cancer, ovarian cancer, breast cancer, cervical cancer, squamous cell carcinoma, brain cancer, prostate cancer and myelodysplastic syndrome; More preferably, the cardiovascular diseases include myocardial hypertrophy, heart failure and arrhythmia.
Citation Information
Cited By
PRMT5 inhibitors and uses thereof
US12448388B2
PRMT5 inhibitors and uses thereof
US12799113B2
